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Biological and physical factors interact to modulate blood response in a wounded vessel, resulting in a
hemostatic clot or an occlusive thrombus. Wall shear stress (τw) and pressure differential (ΔP) across the wound from the
lumen to the extravascular compartment may impact hemostasis. This thesis describes the design of a microfluidic device capable of flowing human
blood over a side channel plugged with collagen (Â± tissue factor) while independently controlling ΔP and τw. Using this device we were able to investigate the impact of
physiologic hemodynamics on the growth and architecture of human blood clots. Our results revealed that both wall shear rate and the transthrombus pressure gradient govern clot development leading to the formation of

two distinct intrathrombus regions; a core of highly-activated platelets and fibrin covered by a shell of less-activated platelets. These regions mimic the activation gradients of clots formed in vivo. We demonstrated that core

development was dependent on the transthrombus pressure gradient restricting thrombin localization while shell development was dependent on wall shear rates. We also found that fibrin polymerization inhibited thrombin

activity at both arterial and venous shear rates. However, the mechanism of this inhibition is shear dependent. At venous shears thrombin activity is inhibited by γ'-fibrin(ogen) binding. While at arterial and pathological shear

rates the clot forms a more dense structure leading to physical trapping of thrombin independent of γ'-fibrin(ogen) binding. Taken together our data supports a model where clot architecture is maintained under various

conditions by shear-specific thrombin inhibition mechanisms. Lastly, we demonstrated that the prevailing hemodynamics dilute ADP and thromboxane to regulate platelet contractility, a newly defined flow sensing

mechanism to regulate clot function.

The field of in vitro hemostasis and thrombosis research has lacked an assay capable of independently
studying the effects of ΔP and local τw on clot development and function. Our microfluidic device bridges this gap, while providing new
insights into the mechanisms of hemostasis and thrombosis, where hemostatic clot development must balance both thrombotic and hemorrhagic risks
in order to rapidly and controllably cease bleeding.
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ABSTRACT
A MICROFLUIDIC APPROACH FOR INVESTIGATING THE ROLE OF
INTRATHROMBUS TRANSPORT IN THROMBOSIS AND HEMOSTASIS
Ryan W. Muthard
Scott L. Diamond

Biological and physical factors interact to modulate blood response in a wounded
vessel, resulting in a hemostatic clot or an occlusive thrombus. Wall shear stress (w) and
pressure differential (P) across the wound from the lumen to the extravascular
compartment may impact hemostasis. This thesis describes the design of a microfluidic
device capable of flowing human blood over a side channel plugged with collagen (±
tissue factor) while independently controlling ΔP and w. Using this device we were able
to investigate the impact of physiologic hemodynamics on the growth and architecture of
human blood clots. Our results revealed that both wall shear rate and the transthrombus
pressure gradient govern clot development leading to the formation of two distinct
intrathrombus regions; a core of highly-activated platelets and fibrin covered by a shell of
less-activated platelets. These regions mimic the activation gradients of clots formed in
vivo. We demonstrated that core development was dependent on the transthrombus
pressure gradient restricting thrombin localization while shell development was
dependent on wall shear rates.

We also found that fibrin polymerization inhibited

thrombin activity at both arterial and venous shear rates. However, the mechanism of this
inhibition is shear dependent. At venous shears thrombin activity is inhibited by ’fibrin(ogen) binding. While at arterial and pathological shear rates the clot forms a more
dense structure leading to physical trapping of thrombin independent of ’-fibrin(ogen)
v

binding. Taken together our data supports a model where clot architecture is maintained
under various conditions by shear-specific thrombin inhibition mechanisms. Lastly, we
demonstrated that the prevailing hemodynamics dilute ADP and thromboxane to regulate
platelet contractility, a newly defined flow sensing mechanism to regulate clot function.
The field of in vitro hemostasis and thrombosis research has lacked an assay
capable of independently studying the effects of ΔP and local w on clot development and
function. Our microfluidic device bridges this gap, while providing new insights into the
mechanisms of hemostasis and thrombosis, where hemostatic clot development must
balance both thrombotic and hemorrhagic risks in order to rapidly and controllably cease
bleeding.
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Chapter 1 : Introduction
1.1 Hemostasis
1.1.1 Platelets
Platelets are anucleate cells that are responsible for hemostasis, or the cessation of
bleeding. The process in which platelets are produced is termed megakaryopoiesis. In
this process, megakaryocytes are derived from hematopoietic stem cells primarily within
the bone marrow.

Following proliferation and differentiation, megakaryocytes go

through a maturation process that ends with the release of new platelets into the
circulation [1].

Healthy whole blood typically contains 150,000-400,000 platelets per

microliter [2]. Human platelets in an unactivated state are typically 2-3 µm in diameter
and have a disk shape [3]. In the presence of platelet agonists, such as collagen or
thrombin, platelets become activated through agonist specific surface receptors.
Activation causes an increase in intracellular calcium resulting in a conformational
change in the platelet cytoskeleton due to interactions between myosin II and actin
filaments [4]. In addition to shape change, platelet activation also initiates secretion of
soluble agonists such as adenosine diphosphate (ADP) and thromboxane A2 (TXA2) [5].
This autocrinic process is important for the recruitment of additional platelets and the
stabilization of deposited platelets during the formation of a stable clot. The timeline of
platelet activation, shape change, and agonist secretion have been studied extensively in
both single platelet and clot formation.
In terms of hemostatic clot growth, initial platelet adhesion and subsequent
aggregation are required for platelet plug formation. Under flow conditions, platelets
1

initially adhere to the site of injury by binding to collagen and/or von Willebrand factor
(vWF). The initial adhesion of platelets is mediated through receptors α2β1 and GPVI
for collagen and αIIbβ3 and GPIb for vWF [6]. Following firm adhesion and platelet
activation, secretion of ADP and TXA2 help recruit additional platelets to the site of
injury. The release of these agonist also help activate integrin αIIbβ3, a critical integrin
for platelet aggregation.

The conformational change of αIIbβ3 to its active state

facilitates the binding of fibrinogen and vWF. These proteins have multiple binding sites
for activated αIIbβ3 which enable more than one platelet to bind the same protein. This
stage is known as aggregation and is vital for the extension of the clot and the cessation
of bleeding [7]. While platelets are aggregating, the local accumulation of agonists
increase the activation level of firmly adhered platelets. This increase in activation
results in cytoskeleton rearrangement into a conformational state that anchors adjoining
platelets tightly together. The contraction of both single platelets and platelets within
regions of high activation securely fastens the clot to the injury site. This prevents
additional bleeding by fortifying the clot, thus preventing it from being torn from the
surface.
Another important aspect of platelets is their ability to provide a surface for
protein binding.

When platelets are activated, the surface of the platelet becomes

negatively charged due to the phospholipids that are transferred from the inner membrane
to the outer membrane [8]. This charge is important for the association of several
proteins that are required for thrombin generation. This step is known as coagulation.

2

1.1.2 Blood Coagulation
Blood coagulation, another important branch of hemostasis, is required for the
generation of thrombin and the formation of fibrin. In this process, proteins known as
coagulation factors work in series and parallel to converge on a common pathway in
order to cleave prothrombin into thrombin. The two paths in the coagulation cascade that
lead to the common pathway are the intrinsic and extrinsic pathways. Both of these
pathways lead to the generation of activated factor X (Factor Xa) [9, 10].
The intrinsic pathway, also known as the contact pathway, is initiated with a
negatively charged surface. At the injury site, activated platelets or damaged smooth
muscle cells/endothelial cells provide a negatively charged phospholipid surface that
converts Factor XII to Factor XIIa. This activation step then facilitates the cleavage of
Factor XI to Factor XIa. Following these events, the intrinsic tenase complex is formed
by Factor IXa and its cofactor, Factor VIIIa. This complex rapidly cleaves Factor X to
Factor Xa [9]. If any of these factors are deficient or are defective, the production of
thrombin via the intrinsic pathway is significantly hindered. Examples of this include
hemophilia A, hemophilia B, and hemophilia C, diseases in which blood is deficient in or
contain defective factors VIII, IX, and XI respectively [11]. While these disorders often
present with a bleeding phenotype if they are severe, the extrinsic pathway can often
alleviate some of these issues.
The extrinsic pathway, also known as the tissue factor pathway, is well regarded
as the dominating pathway for thrombin generation in vivo. The exposure of tissue factor
(TF) on the cell surface initiates the extrinsic pathway at the site of vascular injury.
3

Circulating Factor VII associates with the cell bound TF and is then activated by one of
several coagulation proteases (IIa, Xa, IXa, XIIa, VIIa-TF). Once activated, the extrinsic
tenase facilitates a burst of thrombin production by rapidly cleaving Factor X to Factor
Xa. In addition to Factor Xa generation, the extrinsic tenase also facilitates the cleavage
of Factor IX to Factor IXa. This cleavage helps bypass the requirement of intrinsic
coagulation Factors XIIa and XIa [10].
The common pathway requires Factor Xa which is generated by either or both the
intrinsic and extrinsic tenase. Factor Xa associates with the activated protein cofactor,
Factor Va on a negatively charged membrane surface. This complex is known as the
prothrombinase complex. Following assembly, the prothrombinase can efficiently cleave
prothrombin into thrombin [12]. The generation of thrombin facilitates the enzymatic
cleavage of fibrinogen into fibrin monomer. As fibrin monomer is produced, it then
polymerizes both laterally and longitudinally to form fibers which are important for
additional clot strength and support [13]. The formation of fibrin is the primary goal of
the coagulation cascade and is critical for stabilizing the developing clot and ceasing
bleeding.
1.1.3 Vasculature
The vasculature also plays an important role in hemostasis. During vessel injury,
smooth muscle cells contract to limit blood flow through the injured vessel.

This

response is mediated by endothelial cells and platelets near the site of injury. These cells
release stimuli such as endothelin and TXA2 to induce vessel constriction [14]. The drop

4

in flow through the vessel prevents unnecessary blood loss while maintaining a supply of
platelets and coagulation proteins to facilitate proper hemostasis.
1.2 Thrombosis
An important part of the hemostatic process is the regulation of the platelet and
coagulation response. If either one of these regulatory responses are dysfunctional, clot
growth and/or thrombin generation may result in thrombosis, the prevention of blood
flow through a vessel by an occlusive thrombus. There are two types of thrombosis, one
which occurs within a vein (venous thrombosis) and one which occurs within an artery
(arterial thrombosis). One of the most prevalent forms of venous thrombosis is deep vein
thrombosis (DVT). Risk factors for DVT typically include immobilization, surgery, or
cancer [15]. Prophylaxis is often effective and is typically achieved with anticoagulant
drugs such as heparin or vitamin K antagonists [16]. Arterial thrombosis is similar to
venous thrombosis with the distinction that the occlusive event occurs within an artery.
The primary example of arterial thrombosis is myocardial infarction or a heart attack.
This is an event which prevents blood flow to a part of the heart. Patients experiencing
myocardial infarctions usually present with atherosclerosis, a chronic disease associated
with a plaque buildup in the arteries [17]. The accumulation of plaque in the arterial
blood vessel wall can lead to a lesion within a stenosed vessel that will eventually
rupture. At the point of rupture, the narrow channel quickly becomes occluded with
platelets and fibrin, preventing blood flow to the heart.

Typical prophylaxis for

myocardial infarctions include antiplatelet drugs, stents, and bypass surgery [18, 19].
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In both conditions, one of the major concerns is that the occlusive clot may
embolize, an event known as thromboembolism. This type of event is caused by a clot
that breaks free from an upstream injury site and eventually becomes lodged in a
downstream vessel. Thromboembolism is particular concerning in patients with DVT or
myocardial infarction. If the thrombus embolizes and travels to the lungs or to the brain,
the patient is at risk for pulmonary embolism or stroke respectively. Both of these
conditions can be fatal. Understanding the physical and biochemical properties that
regulate thrombosis and/or thromboembolism may lead to improved patient care and
outcome, making this field of study critical in the research community.
1.3 Transport in Hemostasis
1.3.1 Hemodynamics
Hemodynamics is the study of circulation and the physical forces that govern
blood flow. These forces vary throughout the vasculature, creating diverse environments
in which platelets must respond and thrombin must be generated in order to achieve
proper hemostasis. Blood is composed of red blood cells, platelets, white blood cells, and
plasma. In a healthy individual, the plasma portion of blood normally makes up 55-60%
of the total volume. The cells and plasma proteins in blood give it characteristics that
make it a non-Newtonian fluid. In particular, blood is a shear-thinning fluid. As shear
rates increases, the viscosity of blood is decreases. For simplicity, blood is often treated
as a Newtonian fluid where viscosity is constant for all shear rates. This assumption is
valid when shear rates are greater than 50 s-1 [20]. Wall shear rate is an important term in
hemodynamics because it is dependent on the blood velocity and the vessel diameter.
6

The Navier-Stokes equation describes the velocity field for a Newtonian fluid at motion
in a cylindrical vessel:

Eqn. 1-1

𝜕𝑣

𝜌 ( 𝜕𝑡𝑧 + 𝑣𝑟

𝜕𝑣𝑧
𝜕𝑟

+

𝑣𝜃 𝜕𝑣𝑧
𝑟 𝜕𝜃

+ 𝑣𝑧

𝜕𝑣𝑧

1 𝜕

) = −∇𝑝 + 𝜇 (𝑟 𝜕𝑟 (𝑟
𝜕𝑧

𝜕𝑣𝑧

1 𝜕2 𝑣𝑧

) + 𝑟2
𝜕𝑟

𝜕𝜃2

+

𝜕2 𝑣𝑧
𝜕𝑧 2

)

where 𝜌 is the fluid density, 𝑣𝑧 is the fluid velocity in the flow direction, 𝑣𝑟 is the fluid
velocity in the radial direction, 𝑣𝜃 is the fluid velocity in the tangential direction, 𝑝 is the
pressure, and 𝜇 is the dynamic viscosity.
In the case of blood flow, the velocity of the blood through a given vessel
diameter is driven by the pressure drop along the length of the vessel. An exact solution
for Eqn. 1-1 can be derived to determine the mean blood velocity in terms of vessel
pressure drop. The first requirement is that the flow must be fully developed, meaning
𝜕𝑣

that velocity is not changing in the flow direction ( 𝜕𝑧𝑧 = 0). This assumption holds true
due to the laminar characteristics of blood flow. Laminar flows are more predictable and
have more of a dependence on viscous force than turbulent flows, which depend more on
inertial forces. When flow is laminar the entrance length containing velocity changes in
the flow direction is on the order of the vessel radius [21]. This is typically much smaller
than the length of the vessel. The second requirement is that the flow is steady. This
𝜕

means that the velocity field is not changing with time (𝜕𝑡 = 0). This assumption is valid
in smaller vessels such as the arterioles and venules where the pulsatility of the
circulatory system is minimized [22]. In larger vessels such as the aorta or inferior vena
cava, the pumping of the heart results in pulsatile flow due to the transient pressure
7

supply. The final assumptions are that the radial (𝑣𝑟 = 0) and tangential components
𝜕

(𝑣𝜃 = 0) of the fluid velocity are zero and flow is axisymmetric (𝜕𝜃 = 0).

These

assumptions are valid for unidirectional flow, where there is no rotational component of
the velocity. The laminar flow characteristics within smaller blood vessels minimizes the
rotational component of velocity. Alternatively, this assumption fails in flows near the
heart and at bifurcations where flow characteristics begin to transition from the laminar
regime to the turbulent regime. In small vessels such as arterioles and venules, blood
velocity can be calculated with the Hagen-Poiseuille equation:
Eqn. 1-2

∆𝑃 =

32𝜇𝐿𝑣
𝐷2

where ∆𝑃 is the pressure difference from the beginning to the end of the vessel, 𝜇 is the
dynamic viscosity, 𝐿 is the vessel length, 𝑣 is the mean blood velocity, and 𝐷 is the
vessel diameter. In this equation, the blood velocity depends on the diameter, length and
pressure drop in the vessel. Lumen pressure and diameter vary in both the arterial and
venous circulation. Typically, blood velocity is higher in the arterial circulation than the
venous circulation leading to higher shear rates in the arterial vessels rather than the
venous vessels.

The increase in shear is caused by the increased pressure drop.

Literature values for arterial shear rates normally are given in the range of 700-2000 s-1
while venous shear rates are usually around 200 s-1 [23]. In pathophysiology, narrowed
or stenosed vessels can experience shear rates in excess of 100,000 s-1 [24].
While shear rate is important in terms of the convective delivery of platelets to the
injury site, the pressure gradient between the lumen and the interstitial space drives
8

bleeding out of the vessel. In physiology, these pressure gradients can vary depending on
the location of the injured vessel. For example, capillary blood pressure can range from
25 mm Hg to 90 mm Hg between the head and feet due to gravity [25]. Depending on
lumen diameter, arterioles usually range from 50-85 mm Hg while venules range from
20-30 mm Hg [23]. The interstitial pressure is not as sensitive, usually ranging from -2
mm Hg to 10 mm Hg [26]. This places the range of pressure gradients between the
lumen and extravascular space roughly between 10-85 mm Hg.

In order to cease

bleeding, clots must prevent these pressure gradients from driving blood loss. They
accomplish this by tightly packing together to create a porous media that increases the
resistance to flow.
1.3.2 Porous Media Transport
Porous materials are composed of a solid matrix with a pore or void space filled
with fluid. These materials are typically characterized by their porosity and permeability.
Porosity is defined as the ratio of empty or void volume divided by the total volume of
both the fluid and solid. Depending on the structure of the solid matrix, porosity can
range from 0 to 1. In vivo clot porosity has been calculated experimentally and is
typically within a range between 0.4-0.7 depending on the location of the measurement
within the clot [27]. The other characteristic used to define porous media is permeability.
The permeability of a porous material is defined by the material’s ability to permit fluid
flow through the structure. Permeability has been estimated to be within the range of 1011

– 10-13 cm2 for compacted coronary thrombi [28].
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Porosity and permeability can be used to predict protein and fluid transport within
and through blood clots. Protein transport is influenced by the protein’s diffusivity
within the clot and the fluid velocity through clot. The diffusion coefficient, or the
diffusivity for the molecule or protein of interest, is a constant used to describe the
proportionality between the molar flux and the concentration gradient of the species. In
porous media, diffusivity of a protein or molecule can be reduced. This is determined by
the effective diffusivity which is dependent on the material porosity, the free diffusion
coefficient, the tortuosity of the material and the constrictivity. The other mode of
transport within clots is the fluid velocity, which can be predicted by Darcy’s Law:

Eqn. 1-3

𝑄=

𝜅𝐴∆𝑃
𝜇𝐿

where 𝑄 is the volumetric flow rate, 𝜅 is the material’s permeability, 𝐴 is the crosssectional area to flow, ∆𝑃 is the pressure drop across the media, 𝜇 is the dynamic
viscosity of the fluid, and 𝐿 is the length in which the pressure drop is achieved. Darcy’s
Law was derived from the Navier-Stokes equation (Eqn 1-1) by assuming that the flow
through the clot is an incompressible, creeping flow and the porous media is isotropic. In
a creeping flow, inertial forces are small compared to the viscous forces and

𝐷(𝜌𝑣𝑖 )
𝐷𝑡

~0.

This assumptions is valid due to the slow flow velocities and small length scales for
porous media transport in clots.
While both advection and diffusion can drive protein transport, it is often
beneficial to understand if one of these forces dominates the transport of protein in
porous media. This can be characterized by the Péclet number:
10

Eqn. 1-4

𝑃𝑒 =

𝐿𝑈
𝐷

where 𝐿 is the characteristic length, 𝑈 is the velocity, and 𝐷 is the diffusion coefficient.
The Péclet number is a dimensionless number that compares the ratio of advective
transport to the diffusive transport. A low Péclet number (Pe<<1) is representative of
transport that is dominated by diffusion while a high Péclet number (Pe>>1) is
representative of transport that is dominated by advection forces. The permeability,
porosity, and the resulting Péclet number are important parameters needed to better
understand how protein and agonist are transported within clots as they develop under
flow.

New methods are required to accurately measure these parameters under

hemodynamic conditions and at the micron scale.
1.4 Experimental Techniques for Hemostasis Under Physiologic Conditions
With the advances in technology, hemostasis measurements under physiologic
conditions have become more reliable both in vitro and in vivo. Two in vivo methods that
have become the standard for hemostatic measurements are the tail bleed assay and the
mouse cremaster laser injury model [27, 29]. The tail bleeding assay has existed for over
60 years [30]. This assay focuses on the time that it takes for bleeding to cease from the
tip of a mouse tail that has been amputated or incised.
cremaster laser injury model has been utilized [27].

More recently, the mouse
This model facilitates the

microscopic observation of platelet and coagulation function as they work together to
form a stable clot on the injured vessel wall.

In both of these injury models, the

hemostatic response is measured by the platelets, coagulation, and vasculatures ability to
cease bleeding under physiologic conditions.
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In vitro models of hemostasis have drastically improved with the development of
both photo and soft lithography techniques.

These techniques have facilitated the

production of geometrically controllable chips with micron scale resolution.

The

channels within the chips, also known as microfluidic devices, are designed to control
and manipulate small volumes of fluid.

This makes them ideal for studying

hemodynamics. Previous work has pioneered the use of blood and study of thrombus
formation within microfluidic channels [31]. In these studies, the wall shear rate was
controlled to better understand the significance of these rates on thrombus formation.
The ability to control hemodynamic conditions and localize thrombus formation, for
microscopic imaging, makes microfluidics an ideal system for characterizing the role that
physical forces have on clot development.
While these models all have their strengths and weaknesses, we were motivated to
design and validate a new microfluidic assay to independently control both wall shear
rate and transthrombus pressure gradients.

The merging of previous microfluidic

techniques with control of the hemodynamics represented in the laser injury model would
provide us with a platform to understand the role of protein transport within clots formed
under physiologic conditions. Insights into the transport mechanisms that are utilized by
clots formed under hemodynamic conditions will be crucial for improved drug design and
treatment of thrombotic events.
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Chapter 2 : Side view thrombosis microfluidic device with controllable wall shear
rate and transthrombus pressure gradient
2.1 Introduction
At the onset of vessel injury, collagen and subendothelial matrix become exposed
to flowing blood. Hemostasis is maintained by platelet adhesion and aggregation at the
site of injury [32], along with thrombin production triggered by extravascular tissue
factor. The local physical and biological stimuli present during this development play a
critical role in the final clot structure and function. One important physical parameter
that has long been recognized is the prevailing wall shear stress (w) [33], with the venous
system having lower wall shear stresses than the arterial system [23]. Often absent in the
design of in vitro models is the transthrombus pressure gradient (ΔP) that exists between
the intraluminal space and the interstitial compartment of vascularized tissue.
Incorporating this feature into thrombus development could quickly change the profile of
soluble species, resulting in altered clot structures.
In recent years, several in vivo studies have demonstrated the importance of
interstitial pressure and flow on angiogenesis [34, 35]. This research has benefited from
the ability to control physical factors such as pressure gradients and shear rates using in
vitro microfluidic devices. Previous work illustrated control of these parameters but at
levels not representative of the arterial vasculature [36]. Others have shown control of w
or ΔP, but decoupling their dependence at high and low shear stress is a difficult task [31,
37]. Independently controlling both pressure gradients and wall shear stresses at arterial
or venous conditions would provide an important understanding of hemostasis in blood
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vessel microenvironments. There have not been any devices that incorporate this level of
control.
We were able to design and validate a microfluidic device capable of
independently controlling the wall shear stress and trans-scaffold pressure gradient.
Localization of collagen ± tissue factor (TF) in the scaffold region of the device allowed
side view imaging of thrombosis under controlled transthrombus pressure drops. At
arterial wall shear stress, small increases in transthrombus pressure gradients significantly
reduced average platelet and platelet/fibrin clot heights. Similarly, the periphery and
quantity of thrombin within the clot was reduced in the presence of increased
transthrombus permeation. Permeability measurements were obtained under flow by
utilizing dye pulsing. The collagen scaffold permeability was validated with previous
literature values and new measurements of platelet and platelet/fibrin clot permeability
were calculated at various pressure drops. We demonstrate the ability to independently
control trans-scaffold pressure gradients and wall shear stresses for studying the
permeation effects and rates on or through thrombi.
2.2 Materials and Methods
2.2.1 Device Fabrication and Design
Polydimethylsiloxane (PDMS) (Ellsworth Adhesives) microfluidic devices were
fabricated using previously described soft lithography techniques [38].

In brief,

photolithography was used to preferentially pattern negative photoresist (KMPR 1050,
MicroChem Corp.) on a silicon wafer (D = 100 mm, WRS Materials). The photoresist
was spun to a height of 60 μm then soft baked for 20 min. Following baking, the
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substrate was placed beneath a photomask and exposed to UV illumination. Prior to
development (AZ® 300 MIF, AZ Electronic Materials USA Corp.), the substrate was
baked for 4 minutes at 100 oC. PDMS, with a base to curing agent ratio of 10:1, was then
molded on the substrate for 2 hr at 80oC. Inlet/outlet and pressure ports (Figure 2-1A)
were cut out using 0.75 and 0.5 mm I.D. corers (Harris Uni-Core™, Ted Pella, Inc.),
respectively. PDMS-tubing (0.020” ID x 0.060” OD, Cole-Parmer) connections were
made via 90o, 23 gauge x 1/2” length blunt needles (Small Parts).
The device was designed with a primary channel (60 μm high x 250 μm wide)
connected to two inlets (upstream, downstream), two outlets (scaffold, channel), and
three pressure ports (P1, P2, P3). The upstream inlet was used for fluid that will come in
direct contact with the scaffold while the downstream inlet, prior to the compressed
channel (200 μm wide), was added to create resistance to flow upstream (Figure 2-1A).
The added resistance caused increased pressure due to the constant volume syringe
pumps. Two pressure ports were added upstream (P2) and downstream (P1) of the
scaffold region to accurately measure the pressure at the scaffold-channel interface. An
additional pressure port (P3) was placed next to the scaffold outlet port to determine the
pressure drop across the region. The scaffold was designed with an array of posts (D =
50 μm) spaced 20 μm apart with a narrowed opening from L = 250 μm at the interface to
L=50 μm at the exit (Figure 2-1B). The posts positions were ideal for uniformly loading
collagen fibers and the compressed exit forced the majority of the pressure drop across
the scaffold rather than the exiting channel. Post arrays were placed surrounding each of
the channel setups to support the negative pressure due to vacuum sealing to glass slides
15

(Figure 2-1C). All of the design features in this device made it possible to monitor and
control the pressure gradients across the scaffold, while maintaining constant wall shear
stress at the interface.
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Figure 2-1

A microfluidic device with controllable trans-scaffold pressure
gradients.

Syringe pump inlet Q1 provided a constant volume flow that exited through the
downstream outlet or transversed the collagen region towards the outlet monitored by P 3
(A). The main flow channel (H=60 μm, W=250 μm) provided a collagen-fluid flow
interface between pressure sensors P2 and P1 (B). A LabVIEW control panel interpreted
the pressure measurements (P1, P2, P3) and proportionately controlled a constant volume
syringe pump (Q2) to maintain constant pressure gradients across the collagen region.
Prior to use, the PDMS microfluidic device was vacuum sealed to a glass slide and
connections between the tubing and device were made via 90o, 23-gauge blunt needle tips
(C).
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2.2.2 Device Operation
Devices were vacuum sealed to Sigmacote® (Sigma-Aldrich) treated glass slides
and channels were coated with a 10% BSA solution for 30 min. Polymerized fibrillar
collagen was prepared overnight by incubating (37 oC) an 8:1:1 ratio of collagen (3
mg/ml monomeric, human Type I) (Vitrocol, Advanced BioMatrix, Inc.), 10x PBS, and
0.09M NaOH respectively.

Tissue factor liposomes were prepared as previously

described [38, 39]. Briefly, biotinylated anti-collagen (4 μg/ml, Abcam) and streptavidin
(10 μg/ml, Sigma-Aldrich) were mixed subsequently in a 1:10 volumetric ratio with
polymerized collagen.
biotinylated/TF

Following a 5 min room temperature incubation for each,

liposomes

(79:20:1,

L-α-phosphatidylcholine

(PC):L-α-

phosphatidylserine (PS):biotinylated phosphatidylethanolamine (bPE), Avanti Polar
Lipids) were mixed in a 1:20 ratio by volume with the polymerized collagen/biotinylated
anti-collagen/streptavidin mixture.

The solution was incubated for an additional 10

minutes at room temperature. Device scaffolds were then loaded by pulling 2.5 μL of
polymerized collagen (±TF liposomes) through pressure ports P1 and P2 out of the
scaffold region exit. Immediately following loading, Ca2+ buffer (5mM) was rinsed
through the channels to remove any collagen outside of the scaffold. Devices were setup
on a slide holder for imaging using a CCD camera (ORCA-ER, Hamamatsu) on an
inverted microscope (IX81, Olympus America Inc.).
The loaded channel was then connected to the three pressure sensors (P1, P2, P3)
and the upstream and downstream syringe pumps as previously discussed. The flow rate
from the upstream pump (PHD Ultra, Harvard Apparatus) provided a constant initial wall
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shear stress (33.9 dyne/cm2) at the scaffold by setting a constant flow rate (13 μl/min).
Pressure transducers (Honeywell Sensing and Control) connected at the P 1, P2, and P3
ports transmitted analog voltage signals to a data acquisition device (NI USB-6210,
National Instruments) that was used to process the measurements in LabVIEW (National
Instruments, Figure 2-2).

The flow rate from the downstream pump (PHD 2000,

Harvard Apparatus) was controlled proportionately according to the real-time pressure
measurements (Figure 2-3 and Figure 2-4). This control allowed the device to maintain
constant pressure drop across the scaffold throughout the experiment.

19

Figure 2-2

A LabVIEW program to measure and control microfluidic pressure
gradients.

A user interface was developed to monitor instantaneous pressure measurements inside of
the microfluidic channel at three independent pressure sensors. The pressure transducers
outputted voltage signals that were then converted into pressure. The pressures were
monitored and controlled proportionally by a proportional gain constant (Kp) that
produced a resulting flow rate required to maintain the pressure gradient set point. The
interface continuously displayed the resulting voltage, pressure, and flow rate (A). The
underlying block diagram illustrates the voltage to pressure signal conversion and the
proportionate controller used to calculate the required buffer infusion flow rate (B).
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Figure 2-3

A customized LabVIEW interface for controlling syringe pump flow
rates to maintain a pressure gradient set point.

This interface directly controls a Harvard Apparatus PHD 2000 syringe pump allowing
computer input of the infusion rate, refill rate, syringe diameter, pumping direction, and
on/off. For the purpose of controlling microfluidic pressure gradients, the interface was
supplemented with inputs for pressure set point, proportional gain, output high, and
output low. Prior to imaging under flow, this interface was initiated (Run/Stop) and
device pressure gradients were stabilized at the desired set point.
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Figure 2-4

A LabVIEW block diagram utilized to control a Harvard Apparatus
PHD 2000 syringe pump.

This block diagram was supplemented with code to control the output infusion rate based
on an externally designed proportional controller interface using instantaneous
microfluidic pressure measurements. The external program measures pressure and
calculates an adjusted flow rate necessary to proportionally control the pressure gradient
at the desired set point. The flow rate is passed to this interface which continuously
updates the pump infusion rate every 0.5 s, allowing the microfluidic pressure gradients
to remain constant.
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2.2.3 Device Validation
Pressure transducers were calibrated between 0-1 psig in LabVIEW using
atmospheric pressure and 27.7 inches of H2O respectively. The device was validated by
measuring the permeability of collagen loaded in the scaffold. An injection valve (V450, IDEX Health & Science LLC) was placed between the syringe pump and the
microfluidic channel (Q1) to produce a controlled pulse under constant flow. The average
velocity through the scaffold was measured by pulsing ~25 µL of sulforhodamine 101
acid chloride (Texas Red, Sigma-Aldrich) in 5 mM Ca2+ buffer through the channel and
monitoring dye FI at the inlet and outlet of the collagen scaffold. Measuring the average
velocity through the collagen allowed permeability to be calculated over the complex
domain using COMSOL Multiphysics software. The resulting collagen permeability was
validated by comparisons to previously determined literature values [41, 42].

The

permeability of platelet and platelet/fibrin deposited layers could then be measured using
similar techniques by pulsing ~25 µL of fluorescein isothiocyanate (FITC, SigmaAldrich) in Ca2+ buffer (5 mM) following 10 minutes of whole blood flow (1130 s-1) at a
range of physiologic pressure drops [25, 26].
2.2.4 Blood Collection
Blood draws were in accordance with the University of Pennsylvania’s IRB and
all healthy volunteers were self reported as alcohol and medication free. Human blood
was collected from donors directly into anti-coagulant via venipuncture.

Studies

examining the absence of thrombin were completed with 100 μM of the anti-coagulant
Phe-Pro-Arg-chloromethylketone (PPACK, Haematologic Technologies Inc.) and 1
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μg/ml of a fluorescently conjugated anti-CD41 monoclonal antibody (Abd Serotec).
Uninhibited thrombin studies were completed in 40 μg/ml of the anti-coagulant corn
trypsin inhibitor (CTI, Haematologic Technologies Inc.) and 0.125 µg/ml of a PEconjugated anti-CD61 antibody (Becton Dickinson Biosciences). CTI-treated blood was
also supplemented with 5 μg/ml of a thrombin sensitive antibody (ThS-Ab) for thrombin
localization studies [43], 0.0625 μg/ml of a PE-conjugated anti-CD62P antibody (Becton
Dickinson Biosciences) for P-selectin studies, and 0.5 µg/ml of a fluorescently
conjugated anti-fibrin antibody (gift from the M. Poncz, Children’s Hospital of
Philadelphia) for fibrin localization studies [44, 45].
2.2.5 Finite Element Analysis
During the design phase of the microfluidic fabrication, COMSOL Multiphysics
was used to predict the localization of collagen in the scaffold. The entire structure was
modeled and the pressure ports were a source of collagen (C=1) while the remainder of
the ports with exception to the scaffold exit were a source of 5 mM Ca2+ (C=0). The
solution was pulled through the scaffold exit at a velocity (1 mL/min) similar to slowly
pulling with a 1 mL syringe. Velocity profiles and concentration localization plots were
used to predict the best suited scaffold design. COMSOL was also used to calculate clot
wall shear stress on experimentally defined clot structures at two minute time intervals.
Three-dimensional simulations were modeled using experimental clot structures in a 250
µm wide x 60 µm high channel. The inlet flow rate was set to 13 µL/min and the middle
60% of the clot surface was averaged over 100 equal spaced lines scans for each time
dependent structure. In an independent measurement, COMSOL was used to calculate
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permeability [45]. Briefly, the pulsed dye buffer was modeled using the stationary
Navier-Stokes equation for laminar flow.

The collagen, platelet deposit, and

platelet/fibrin structures were simulated using Darcy’s law:

Eqn. 2-1

𝜅
𝒖 = − 𝛻𝑝
𝜇

where 𝒖 is the fluid velocity, 𝜅 is the Darcy’s permeability, 𝜇 is the buffer viscosity, and
𝑝 is the pressure. Coupling the Navier-Stokes equation with Eqn. 2-1 allowed Darcy’s
permeability (𝜅) to be iteratively calculated by minimizing the squared error between the
mean experimental and simulated fluid velocity through the porous media.
2.3 Results
2.3.1 Controllable transcollagen scaffold ΔP in a side view thrombosis device
A microfluidic device was designed with the ability to maintain a computercontrolled trans-scaffold pressure gradient of ΔP = (P2+P1)/2 – P3, while providing
constant wall shear stress w (Figure 2-1). The pressure gradient and wall shear stress
were controlled by utilizing two independent syringe pumps (Q1, Q2), three pressure
sensors (P1, P2, P3), and a proportional controller in LabVIEW (Figure 2-2-Figure 2-4)
to control Q2 based on P1, P2, and P3 at constant Q1. The syringe pump upstream of the
scaffold region dictated the wall shear stress while the downstream syringe pump
controlled the channel pressure for independent control of ΔP and w.
The scaffold region was designed with six posts equally spaced in a triangular
orientation (Figure 2-1B and Figure 2-5) to support the loading of fibrous matrix
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materials such as polymerized collagen. Pressure ports upstream (P2) and downstream
(P1) of the scaffold were used for even infusion of a collagen solution during the loading
protocol by withdrawal from port P3 (Figure 2-5A). With Q1 and Q2 = 0, the velocity
profile throughout the posts initially focuses collagen loading in the middle of the
scaffold where the velocities are roughly twice as fast as the edges (Figure 2-5B). As
the middle region is loaded, the edge velocities start to dominate resulting in a uniform
distribution of collagen at the interface of the main channel (Figure 2-5C).

This

approach provided a reliable and repeatable method to create a defined protein matrix to
trigger reactions during the subsequent perfusion of whole blood using Q1.
After collagen was loaded into the device, the ΔP controller algorithm was
optimized under diverse conditions. First, the proportionate control parameter Kp was
determined to be 0.92 μL/min·Pa using manual tuning to maximize response speed and
minimize overshoot. The maximum buffer flow rate was set to 100 µl/min to prevent
overshooting the set point. Robust control of trans-scaffold ΔP set points was obtained
under arterial (1130 s-1, 13 µL/min) or venous (174 s-1, 2 µL/min) wall shear rates
(Figure 2-6A) using whole blood perfusion. A range of ΔP values from 20.6 to 30 mm
Hg were achieved at an arterial shear rate. Similarly, a range of ΔP values from 11.3 to
22.5 mm Hg were achieved at a venous shear rate. The average response rate was 0.26
mm Hg/s during set point changes. Lower wall shear stress required higher buffer flow
rates to reach larger pressure gradients which caused reduced response rates (0.20 mm
Hg/s) compared to arterial wall shear stress (0.31 mm Hg/s).
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Throughout these

experiments P2 and P1 typically differed by less than 1 mm Hg while P3 remained
relatively constant.
For measurement of clot permeability, pulsing of a fluorescent solute tracer under
constant flow rate was required. This feature was examined by measuring the transscaffold pressure gradient and buffer flow rate during the injection of a fluorescent dye
solution at a lower viscosity (µDye=0.001 Pa·s) than that of whole blood (µBlood=0.003
Pa·s) (Figure 2-6B) [47]. Prior to the introduction of dye (<1 min), the blood viscosity
in the channel and the Q2 flow rate were constant. As the dye in buffer solution began to
exceed the blood concentration (1-3 min, Figure 2-6C), the viscosity of the mixture
began to drop. This drop in viscosity was met with an increase in the Q2 flow rate to
compensate for the reduction in resistance against the Q1 syringe pump. When the blood
began to exceed the dye/buffer solution (>3 min), the viscosity began to increase and the
Q2 flow rate began to decrease to provide a constant resistance against the Q1 syringe
pump.

Throughout all of these viscosity changes the pressure drop in the channel

remained constant (23.5 ± 0.12 mm Hg) due to the constant downstream resistance
maintained by the Q2 flow rate. The ΔP range that we investigated mimics the range
located in capillaries. At the head or heart level lumen pressures are generally 25-30 mm
Hg [25] and interstitial pressures are within -2-10 mm Hg [26]. While this is the ΔP (15
mm Hg to 32 mm Hg) we have focused on, higher ΔP values certainly exist in physiology
and can be achieved in this device.
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Figure 2-5

Human type I, polymerized collagen localized in the scaffold region.

Polymerized collagen (2.5 μL) was placed on pressure ports P2 and P1. A 1 mL syringe
was used to pull the solution through the scaffold region allowing fibers to wrap around
the posts. COMSOL simulations demonstrated the normalized concentration and the
limited exposure of collagen in the channel during the loading procedure (A). The initial
velocity field in the scaffold region produces slightly higher velocities in the middle of
the posts which allowed collagen fibers to load the middle of the region before the outer
edges (B). This type of loading resulted in an evenly distributed collagen region with a
flat collagen-fluid flow interface (C).
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Figure 2-6

Syringe pump control allows rapid responses to changes in pressure
set point and fluid viscosity.

Constant Q1 flow rates provide a constant wall shear rate at the collagen-fluid flow
interface. LabVIEW control over Q2, via a downstream syringe pump, allowed pressure
gradients across the scaffold region to remain constant while responding quickly to set
point adjustments (A). In a separate experiment, buffer containing dye was pulsed
through the device. As the lower viscosity buffer became more concentrated than the
blood, the Q2 flow rate increased to maintain pressure at the desired set point (B). The
increase in normalized dye fluorescence intensity corresponded to the decrease in
viscosity and the increase in the downstream flow rate Q2 (C).
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2.3.2 Transthrombus permeation reduces the intrathrombus zone of thrombin
activity
Thrombus development at the collagen or collagen/TF scaffold was followed for
10 min with a trans-scaffold pressure drop of 23.4 mm Hg. During the perfusion of
PPACK anti-coagulated whole blood at an initial wall shear stress of 33.9 dyne/cm2, the
thrombin deficient clot formed a uniform layer at the collagen/blood interface (Figure
2-7A-C). When TF was added to the collagen scaffold and PPACK was replaced with
CTI, the clot favored larger upstream and downstream platelet deposits rather than the
uniformity seen in thrombin deficient clots (Figure 2-7D-F). Using a thrombin sensing
anti-platelet antibody, we were able to clearly show the thrombin rich layer within the
clot near the collagen/TF interface during transthrombus permeation. The clot structure
was then modeled in COMSOL to analyze the resulting wall shear stress at the surface of
the clot following 9 minutes of flow. Due to the shape of the thrombus, the maximum
shear stress (138 dynes/cm2) was located at the leading edge of the clot and was ~4-fold
larger than the average clot shear stress (Figure 2-7G).
Using the platelet-targeted thrombin sensor added to CTI-treated whole blood, the
thrombin rich region was further analyzed at trans-scaffold ΔP = 0 and 23.4 mm Hg. The
thrombin sensor provides a cumulative readout of local thrombin activity. Fluorescent
line scans from the collagen interface (width=0 microns) and across the clot into the
blood flow (width=45 microns) were averaged over the entire front-to-back length of the
clot.

In a diffusion-controlled transport process lacking transthrombus interstitial

permeation (ΔP=0 mm Hg), the thrombin concentration and boundary thickness were
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~62% and ~59% larger, respectively, compared to that of clots formed with
transthrombus permeation (ΔP = 23.4 mm Hg) (Figure 2-8A and Figure 2-8B). This
drastic difference demonstrates the importance that transthrombus permeation has on
soluble agonist localization. Since an inert protein the size of thrombin (DBrownian ~ 7 x
10-7 cm2/s) would be expected to diffuse more than 100 microns in 4 minutes, the
restricted ~15-micron thick region of thrombin activity in Figure 2-8 indicates a
combination of rapid inhibition by antithrombin, sequestration within fibrin, restricted
diffusion by platelets, and/or platelet binding (eg. platelet GPIbα). In addition to the
thrombin studies, P-selectin positive platelets were also identified. Figure 2-9 compares
hierarchical clot architecture using human blood in vitro with previously reported in vivo
mouse laser injury model [27], demonstrating a remarkable correspondence between
these two independent approaches, namely the formation of a P-selectin-positive core and
a surrounding P-selectin-negative shell. This is the first microfluidic device to recreate
with human blood the core/shell architecture originally characterized in mouse blood
vessels.
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Figure 2-7

Perfusion of anti-coagulated whole blood provides reproducible
thrombus development at the collagen-blood interface.

Anti-coagulated whole blood was perfused at an initial wall shear stress (33.9 dyne/cm 2)
while a constant ΔP (23.4 mm Hg) was maintained across the collagen-blood interface.
Dynamic studies of platelet (red) and thrombin (green) development on collagen (A-C) or
collagen/TF scaffolds (D-F) allowed for spatial-temporal clot measurements. Resulting
structures were simulated in COMSOL to study time-dependent wall shear stress at the
clot boundary (G).
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Figure 2-8

Increasing transthrombus pressure gradients caused a reduction in
thrombin.

Average line scans of the thrombin boundary layer were taken every two minutes during
clot formation on a collagen/TF surface. Whole blood anti-coagulated with CTI was
perfused for 10 minutes and transthrombus pressure gradients were maintained at ΔP=0
mm Hg (A) or ΔP=23.4 mm Hg (B). The increased convection through the clot caused a
reduction in the presence and velocity of thrombin towards the clot surface.
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Figure 2-9

Clots formed in the microfluidic injury model we present illustrate
remarkable correspondence to in vivo hierarchical clot architectures
found in mouse.

Fluorescent P-selectin antibodies (green) were used to determine platelet α-granule
release. Following 10 minutes of whole blood perfusion (200 s-1) with a ΔP=20 mm Hg,
a distinct core of P-selectin positive platelets was covered by a shell of P-selectin
negative platelets (red) in the microfluidic injury assay (A). The clot architecture of a
thrombus in a mouse cremaster injury (21, with permission) demonstrates remarkable
similarities (B). In both assays only the core or P-selectin positive platelets release their
α-granules. This illustrates a level of activation that only the core region of the clot can
reach during transthrombus permeation.
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2.3.3 Pressure gradients affect thrombus composition and size
Using CTI-treated whole blood perfusion, the dynamics of clot composition, wall
shear stress, and average clot height, in the presence (collagen/TF) or absence (collagen)
of thrombin, were investigated at transthrombus pressure gradients of 20.8 mm Hg
(Figure 2-10A-D), 23.4 mm Hg (Figure 2-10E-H), or 0 mm Hg (Figure 2-10I-K). As
the clot grew into the flow field, the wall shear stress increased under the constant flow
rate conditions of the experiment. Since the average clot thickness (up to 50 µm) was
small relative to the channel width (250 µm), the wall shear stress only increased
modestly at constant flow rate. The calculated clot wall shear stress was averaged in the
middle 60% of the clot length.
Comparison of structures formed on collagen versus collagen/TF scaffolds at
constant transthrombus pressure gradients revealed dramatically different structures. At
ΔP = 20.8 mm Hg, the upstream portion of clots on collagen remained larger than the
trailing edge whereas the trailing edge outgrew the upstream edge when whole blood was
exposed to collagen/TF surfaces (Figure 2-10A and Figure 2-10B). In the case of ΔP =
23.4 mm Hg, the clots developed on collagen were relatively uniform along the length of
the clot (Figure 2-10E). At the same pressure, the incorporation of thrombin caused an
initially larger upstream edge that eventually became uniform with the trailing edge
following 10 minutes of perfusion (Figure 2-10F). Noticeably, clots formed without
transthrombus permeation (Figure 2-10I) looked more similar to clots formed on
collagen/TF surfaces at ΔP = 20.8 mm Hg, where the trailing edges protruded further into
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the flow.

This phenomenon has been observed previously in a parallel channel

microfluidic device at arterial wall shear stress [48].
Throughout all experiments, clot height decreased when transthrombus pressure
drop was increased. Interestingly, only an 11% increase in pressure drop (20.8 mm Hg to
23.4 mm Hg) resulted in large percent reductions in final clot height for both collagen
(27.9%, p<0.001) and collagen/TF structures (20.2%, p=0.012) (Figure 2-10C and
Figure 2-10G). This trend continued when clots were formed without permeation. Final
average clot height at ΔP = 0 mm Hg (TF/Collagen surface) was ~12 μm larger than clots
exposed to transthrombus pressure gradients of 23.4 mm Hg (Figure 2-10J).

As

previously discussed in Figure 2-8, the thrombin boundary height was reduced with
increasing ΔP (Figure 2-10G and Figure 2-10J). With the increases in clot heights
came corresponding increases in wall shear stresses from an initial stress of 33.9
dynes/cm2 to 42.3 dynes/cm2 (platelet structures) or 46.9 dynes/cm2 (platelet/fibrin
structures) (Figure 2-10D and Figure 2-10H).
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Figure 2-10

Transthrombus pressure gradients effect dynamic measurements such
as clot structure, wall shear stress and height.

Clots formed on collagen (± TF) with transthrombus pressure gradients of 20.8 mm Hg
(A-D), 23.4 mm Hg (E-H), or 0 mm Hg (I-K) resulted in structural differences based on
the pressure and the presence or absence of TF. Thrombus development on collagen
without TF typically produced smaller clot heights and reduced wall shear stresses.
Reductions in transthrombus pressure gradients resulted in increased thrombin and
platelet deposition heights.
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2.3.4 Fluorescent dye transport allows thrombus permeability measurement
The designed microfluidic device not only allowed a side view analysis of
thrombus development under transthrombus pressure gradients, but it was also a versatile
tool for permeability measurements. In order to analyze permeability measurements for
platelet and platelet/fibrin clots formed under flow, the device was validated comparing
collagen permeability measurements to previous literature values. Measurements were
made by injecting a fluorescent dye into the main channel under continuous flow and
following the progression of the dye at the inlet and outlet of the collagen scaffold. From
these curves, an average velocity was calculated by dividing the distance between
measurements by the time between peak fluorescent intensities on both the inlet and
outlet measurements.

The calculated average velocities were then matched by

minimizing the sum squared error between the predicted velocities through the structure
in COMSOL. The measured permeability for the collagen scaffold was 1.98x10-11 ±
0.64x10-11 cm2. This value was within the range of collagen permeabilities ([41]: 8.9x1011

cm2; [42]: 1x10-11 cm2) previously reported. This measurement was calculated for

trans-scaffold pressure drops of 11.95 mm Hg, 14.15 mm Hg, and 23.43 mm Hg
respectively.
With a validated measurement for the collagen scaffold, the next step was to
measure the permeability of clots formed with and without thrombin. The addition of TF
liposomes to the collagen and substitution of CTI for PPACK allowed us to study
platelet/fibrin clots. Measurements were made identical to the techniques previously
discussed with collagen and the concentration curves were validated by the COMSOL
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model (Figure 2-11A and Figure 2-11B). Without thrombin in the system, the platelet
clot permeability was 5.45x10-14 ± 0.89x10-14 cm2 for ΔP=20.70 mm Hg and 23.53 mm
Hg (Figure 2-11C).

When thrombin was uninhibited, the time between peak dye

intensities from the inlet to the outlet increased from 115s to 280s for the representative
pulse curves. This increase resulted in a platelet/fibrin permeability of 2.71x10 -14 ±
0.38x10-14 cm2 for ΔP=20.76 mm Hg and 23.34 mm Hg (Figure 2-11C). The 50%
reduction in permeability (p=4.6E-4) can be seen by the relative increase in the time
between peak dye intensities in the representative platelet (Δtplatelet=115s) and
platelet/fibrin (Δtplatelet/fibrin=280s) clot curves. COMSOL was utilized to express these
curves and the normalized dye concentration in the device at t=3.33 min (Figure 2-11D),
t=5.33 min (Figure 2-11E), and t=7.33 min (Figure 2-11F) for the representative
platelet/fibrin clot.
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Figure 2-11

Platelet and platelet/fibrin clot permeability was measured by pulsing
fluorescent dyes.

Following platelet deposition, whole blood flow was continuously switched to
fluorescent dye injection. Dye fluorescence intensity was measured at the platelet (A) or
platelet/fibrin (B) interface and collagen exit to predict average fluid velocities across the
structure. The permeability of the collagen scaffold, platelet clot, and platelet/fibrin clot
were calculated using COMSOL to solve for average velocity (C). Normalized dye
fluorescence intensity was demonstrated in COMSOL at the time points indicated (D-F).
The pulse was observed as it permeated through the collagen and platelet/fibrin structure.
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2.4 Discussion
The development of in vitro microfluidic assays and in vivo mouse injury models
have provided many insights into thrombosis and hemostasis under physiologic flow
conditions [31, 48]. While each assay has advantages, a challenge that remains is the
ability to study clot development and permeation at higher and lower physiologic
transthrombus pressure gradients. In the designed microfluidic device, clot development
occurs under permeation while being visualized from the side as in the mouse laser injury
models. The advantage of incorporating these characteristics into a microfluidic model is
the ability to control transthrombus pressure gradients and wall shear stress. This is the
first reported device that facilitates the independent control of both of these important
regulators of clot development at physiologic vessel conditions.
Studies of interstitial flow and its importance in angiogenesis and other cellular
environments have steadily increased over the last decade. Incorporating controllable
pressure gradients and wall shear stress in a model of angiogenesis may provide a more
realistic in vitro representation of the process as it pertains to human physiology. In the
case for thrombosis and hemostasis, minimal changes of transthrombus pressure
gradients revealed a significant change in clot size and structure.

The increase in

transthrombus permeation caused by an increase in pressure gradients resulted in
decreased clot height. The diffusivity of agonists such as thrombin, ADP, and TXA2 play
an important role in these observations.

In a thrombin deficient scenario, platelet

aggregation is primarily achieved by the release of ADP and TXA2 after the initial
adhesion to the exposed collagen. The diffusivity of these molecules is much faster than
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thrombin and as a result, more easily affected by transthrombus permeation [50]. When
thrombin is present, the reduction in clot size is still noticeable at increased pressure
gradients but slightly reduced compared to the previous scenario. This interpretation was
supported by the reduction in thrombin boundary height in clots formed in the presence
of transthrombus permeation. Without pressure gradients, the thrombin was allowed to
diffuse further towards the surface of the clot. This suggests that ADP or TXA2 would
easily reach the clot surface under these conditions but quickly be convected away under
permeation [51].

Studying the dynamics of thrombosis and hemostasis under

transthrombus permeation has allowed for a more thorough investigation of the platelets
response to the physical and biological stimuli present in physiology.
While clot structure and size were affected by pressure gradients, the permeability
of platelet and platelet/fibrin thrombus formed under these conditions remained constant.
Permeability measurements in microfluidic devices are not novel [52], but the
measurement of thrombus permeability under flow certainly is. Previous measurements
have fallen short in their attempt to predict physiologic clot permeability due to the
omission of clot structure and composition only observed under flow [53]. In this device,
these critical features were preserved and clot permeability measurements were obtained
in the presence and absence of thrombin.

The permeability observed in these

measurements compares closely to previous measurements made in rabbit endothelium
[54], suggesting that these clots may be a rapidly developing replacement tissue for the
denuded endothelium. This would allow the necessary wound healing molecules and
cells access to the site of injury while maintaining vessel hemostasis. Incorporation of
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tissue factor allowed clots to quickly intertwine fibrin into their structure and resulted in a
significant reduction in permeability as compared to thrombin/fibrin deficient clots. This
is important because clots formed in low tissue factors areas such as joints may rely
solely on thrombin production from the intrinsic pathway [55]. The reduction in their
permeability allows increased access to the site of injury. The increase in access may be
correlated to cases of joint bleeding in hemophiliacs where thrombin production via the
intrinsic pathway is limited [56]. The device implemented in these studies has proved to
be a great way to measure permeability and the role of pressure gradients on clot
development. Moving forward, this device would provide valuable data to the fields of
angiogenesis and thrombosis, where interstitial permeation plays a critical role in the
functionality of the assay.
2.5 Conclusions
While investigating thrombus development on a collagen or collagen/TF scaffold
we were able to conclude that small reductions in transthrombus pressure drop caused
significant increases in average clot height. This observation was also observed during a
study of agonist localization. In the presence of clot permeation the thrombin boundary
height and intensity were substantially reduced compared to a scenario where diffusion
dominated clot transport. Additionally, measurements for collagen permeability were
validated with previous literature values and clot permeabilities were easily measured
under continuous flow conditions at varying pressure drops. This device provides a novel
system that is translatable to studies requiring independent control of physiologic transscaffold pressure gradients and/or wall shear stresses.
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Chapter 3 : Blood clots are rapidly assembled hemodynamic sensors: flow arrest
triggers intraluminal thrombus contraction
3.1 Introduction
During thrombosis or hemostasis under flow conditions, platelets rapidly deposit
at a site of vascular injury.

The vessel wall and subendothelium quickly become

connected mechanically to the developing thrombus [57]. During vessel wound closure,
this interwoven assembly prevents further blood loss by platelet-mediated clot
contraction and stiffening [58]. Platelets generate contractile forces to allow clots to
match the stiffness of the endothelium [59]. Interactions between myosin II and actin
filaments govern this contraction and are regulated by the activation of myosin light
chain kinase through calcium/calmodulin and/or Rho kinase signaling [60, 61]. During
contraction, force transmission ultimately occurs via talin and α IIbβ3, which binds
platelets via fibrinogen and fibrin [62, 63]. Following clot retraction, the tight seal that is
formed around the injured tissue significantly reduces clot permeability, consequently
limiting the leakage of cells and plasma. Also, the permeability of occlusive clots is
critical to thrombolytic therapy for acute myocardial infarction since permeation dictates
penetration of plasminogen activators [28]. The effects of local hemodynamics on clot
contraction and permeability are poorly understood, yet highly relevant to thrombus
growth, stability, or susceptibility to embolism, fibrinolysis, or bleeding.
Prior studies of clot permeability have used whole blood clots that do not achieve
the 50 to 100-fold increase in platelet concentration on a surface that occurs under flow
conditions [64, 65]. While clot contraction has been studied for decades using clots
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formed in test tubes, there exists a large gap in the fundamental understanding of
mechanisms that initiate and control the response under hemodynamic conditions. In
terms of force-loading of thrombotic structures, platelets respond with larger stall forces
when exposed to stiffer fibrinogen-coated atomic force microscopy (AFM) cantilevers
[59].

Studies of whole clot contraction forces may not necessarily predict clot

contraction dynamics under flow conditions.
We measured, for the first time, clot contractility and permeability under
hemodynamic conditions. The presence of tissue factor caused a significant decrease in
thrombus permeability. Unexpectedly, flow arrest caused enhancement of permeability
for platelet deposits due to a triggered clot contraction and consequent collagen
restructuring. To further examine platelet contraction after flow cessation, a rigid wall
flow device was used.

Platelet deposits were developed and antagonized using

blebbistatin, a myosin II inhibitor and ADP/thromboxane receptor antagonists. Flow
arrest caused an intracellular increase in Ca2+ that preceded contraction and was
dependent on the autocrine signaling of ADP and TXA2. These studies provide new
insight into the ability of platelets to sense local hemodynamic flow based on the
convective-diffusive transport of autocrine signaling molecules.
3.2 Materials and Methods
3.2.1 Reagents
The following reagents and instrumentation were obtained and stored according to
manufacturers’ instructions: polydimethylsiloxane (PDMS) (Ellsworth Adhesives);
sigmacote, streptavidin, sulforhodamine 101 acid chloride (Texas Red), fluorescein
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isothiocyanate (FITC), and 2-MeSAMP (Sigma-Aldrich); human type-1 monomeric
collagen (VitroCol, 3 mg/ml) (Advanced Biomatrix);

equine tendon-derived type-1

fibrillar collagen (Chrono-log); biotinylated goat anti-collagen type I polyclonal antibody
(Abcam); 0.05 µm Fluoresbrite® microspheres (Polysciences Inc.); fluo4-NW (Life
Technologies); blebbistatin (EMD Millipore); SQ 29,548 (Cayman Chemical); MRS2179 (Tocris Bioscience); anti-fibrin antibody (gift from the M. Poncz, Children’s
Hospital of Philadelphia); L-α-phosphatidylserine (PS), L-α-phosphatidylcholine (PC),
and biotinylated phosphatidylethanolamine (bPE) (Avanti Polar Lipids); analog pressure
transducers (Honeywell Sensing and Control).
3.2.2 Blood Collection
All donors were reported as medication free for the previous 10 days and blood
collection was in accordance with the University of Pennsylvania’s IRB. Human blood
from healthy volunteers was collected into 100 µM Phe-Pro-Arg-chloromethylketone
(PPACK, Haematologic Technologies Inc.) or 40 µg/ml corn trypsin inhibitor (CTI,
Haematologic Technologies Inc.). PPACK-treated whole blood was also treated with
fluorescently conjugated anti-CD41 monoclonal antibody purchased (1 µg/ml; Abd
Serotec). PE-conjugated anti-CD61 (0.125 µg/ml; Becton Dickinson Biosciences) and
fluorescently conjugated anti-fibrin antibodies (0.5 µg/ml) were added to CTI-treated
blood as previously described [44, 45].
3.2.3 Permeation device design and manufacture
PDMS was used to construct microfluidic devices following soft lithography
protocols [38] as previously described [31, 40, 48]. The primary blood flow channel (250
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µm wide x 60 µm high) was designed to create flow over a micropost scaffold region as
illustrated in Figure 3-1A. At this micropost scaffold junction, blood could continue
along the primary channel or exit through the scaffold channel (50 µm wide x 60 µm
high) to an outlet port maintained at P3 = atmospheric pressure or blocked so that P3
equals the pressure within the blood flow channel. Real-time pressure measurements
were collected in LabVIEW (National Instruments) using 0-1 psig pressure transducers
upstream (P2), downstream (P1) and exiting the scaffold region (P3) as shown in Figure
3-1.

Channel pressure was controlled using two constant volume syringe pumps

(Harvard Apparatus).

A syringe pump located upstream of the collagen scaffold

delivered anti-coagulated whole blood at an independently controlled initial inlet wall
shear rate (1130 s-1), while a downstream pump perfused Ca2+ buffer (5 mM) at a rate set
by a proportionate controller programmed in LabVIEW.
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Figure 3-1

Microfluidic device to independently control blood flow and
transthrombus pressure drop.

COMSOL was used to determine the pressure throughout the microfluidic device (A)
including the collagen scaffold region (B), where L=250 µm. Human type I polymerized
collagen was localized in the scaffold region (C). Following 10 min of CTI-whole blood
flow at 1130 s-1, platelets (red), fibrin (green) and their overlap (yellow) form a thrombus
on the collagen (D). A confocal image of platelets (red) and fibrin (green) shows the 3D
structure the microfluidic device (E).
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3.2.4 Microfluidic device for thrombus permeation
PDMS devices were sealed to Sigmacote-treated glass slides using vacuumassisted bonding. Type I human monomeric collagen solution was polymerized at 2.4
mg/ml overnight using 8 parts collagen, 1 part 0.09 M NaOH, and 1 part 10x PBS. Prior
to loading the scaffold with collagen, all channels were incubated with 10% BSA for 30
min at room temperature.

Following incubation, well mixed polymerized collagen

solution was pipette on the upstream and downstream pressure ports and localized into
the micropost scaffold region by pulling the solution (2.5 µL) through the scaffold exit
channel with syringe withdraw for ~ 15 s. A fixed amount of collagen (~ 3.3 ng) was
thus deposited on the micropost scaffold. Collagen solution remaining in the channel
region (between P2 and P1) was removed by infusion of Ca2+ buffer (5 mM) from the
blood inlet port prior to instillation of blood for the experiment. For experiments using
collagen with linked tissue factor (TF), biotinylated and TF liposomes (20:79:1,
PS/PC/bPE) were prepared as previously described [40, 48] following the method of
Smith et al. [39]. Polymerized collagen (2.4 mg/ml) was mixed in a 10:1 ratio by volume
with biotinylated anti-collagen (4 μg/ml) and incubated at room temperature for 5
minutes. Streptavidin (10 μg/ml) at a 1:10 volumetric ratio and TF liposomes at a 1:20
volumetric ratio with collagen were sequentially added and incubated for 5 min and 10
min, respectively. The fibrillar collagen/TF solution was then perfused through the
micropost array region as described for fibrillar collagen.
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3.2.5 Permeability Measurements
Whole blood was anti-coagulated with PPACK for perfusion over collagen or
with CTI for perfusion over collagen/TF. Each whole blood perfusion was conducted at
an inlet wall shear rate of 1130 s-1 for 10 min. The transthrombus pressure drop was
immediately set to the controlled value and side view images of the platelet or
platelet/fibrin thrombus were taken at the blood contact region of the collagen scaffold.
Following thrombus development, an injection valve (Idex Health & Science) was
manually switched to pulse Ca2+ buffer (5 mM) containing Texas Red or FITC dye (~25
μL) without disruption of the flow.

Real-time dye, platelet, and fibrin fluorescent

intensities were imaged with an inverted microscope (IX81, Olympus America Inc.)
using a CCD camera (ORCA-ER, Hamamatsu).

Confocal images of platelet/fibrin

thrombus were taken in 2-μm sections, under flow, with a disk-scanning unit (IX2,
Olympus America). ImageJ software was used to analyze all images and develop 3dimensional representations of thrombus.
3.2.6 Contraction Measurements
PPACK-treated whole blood with or without the addition of 50 nm fluorescent
microspheres (1010 beads/ml blood) was perfused through the permeation device at 1130
s-1. Platelet deposits were formed for 10 min under a constant transthrombus pressure
drop (23.5 mm Hg). Whole blood flow was then switched without interruption to Ca2+
buffer (5 mM) flow. Following 4.5 min of buffer flow, both syringe pumps were stopped
and the transthrombus pressure drop immediately approached zero. Platelet deposits
were imaged in 15 sec intervals over 30 min.
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Thrombus contraction studies were also performed in a parallel channel
microfluidic device [31]. Briefly, a microfluidic device was used to print a 250 μm wide
strip of diluted fibrillar collagen lengthwise on a Sigmacote treated glass slide. The
patterning device was removed and second device was positioned with ten parallel
channels (250 μm wide x 60 μm high) perpendicular to the collagen. All channels were
pre-incubated with 0.5% BSA. Anti-coagulated whole blood (PPACK) was treated with
or without an intracellular Ca2+ dye. Fluo4-NW (2.5 mM probenecid) was loaded into
platelets by incubating 1 part dye with 4 parts blood for 45 min. Dye treated or untreated
blood was then placed in the inlets of three channels.

A syringe pumped allowed

simultaneous perfusion of the three channels at an initial wall shear rate of 1160 s-1.
After the collagen patches (250 x 250 μm) were covered with platelets, flow was
immediately switched to Ca2+ buffer (5 mM, 0.01% DMSO) in the presence or absence of
antagonist (blebbistatin or mixtures of SQ-29,548, MRS-2179, 2-MeSAMP). In some
experiments, buffer flow was stopped (30-sec or 1-min) and then reestablished or
completely stopped following 7 min of perfusion. Intracellular Ca2+ fluorescence and
platelet deposit structures were imaged with a 20x objective, in 15 sec intervals, for the
duration of the experiment.
3.2.7 Finite Element Analysis
COMSOL Multiphysics software was used to numerically solve steady state
pressure gradients, blood flow velocities and permeation velocities over complex
geometries (collagen plus thrombus) with constant permeability in the PDMS permeation
device. Blood (ρ=1060 kg/m3, µ=0.003 Pa·s) and buffer (ρ=1000 kg/m3, µ=0.001 Pa·s)
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were both modeled using laminar flow for solution of the Navier-Stokes equation
(Re=0.49, Reelement=0.25). The collagen region was modeled using Darcy’s law (∇2P=0)
with entrance and exit pressures being coupled to the external laminar flow properties
and permeability (κ) set to a previously determined value (eg. κ = 1 x 10 -15 m2) [42].
Flow rates of 13 μL/min for blood and buffer allowed the downstream resistance length
to be modified to achieve ΔP=23.5 mm Hg at the collagen scaffold interface.
Collagen, platelet, and platelet/fibrin permeability were each solved in COMSOL
for the complex geometries of the collagen scaffold and developed thrombus.
Calculating and comparing the permeability of collagen to previously reported values
provided experimental validation of the device [41, 42]. Experimental pressure and
calculated average velocity data were used as input parameters. The square difference
between the experimental and computational average velocity across the collagen
scaffold were iteratively reduced (<0.001 µm2/s2) by varying the collagen permeability.
With the solved collagen permeability, the process was repeated for the platelet or
platelet/fibrin geometry on the collagen.

The normalized dye concentration in the

channel was used as transient input data into the model. Matching the transient pulse
concentration at the collagen output with the experimental output validated the
computational model. As expected, calculated values of κ were not dependent on ΔP.
3.2.8 Statistics
Two-tailed Student’s t-tests were used to calculate all P values. Statistically
significant differences were reported if P < 0.05.
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3.3 Results
3.3.1 Microfluidic device for measuring clot permeability and contractility
A microfluidic device was designed to allow pressure-driven transthrombus
permeation with simultaneous imaging of clot contractile dynamics under flow. The
device has a blood and buffer inlet port, collagen scaffold, and three ports for pressure
readings (P1, P2, P3) up to 50 mm-Hg (Figure 3-1A and Figure 3-2). The downstream
buffer and upstream whole blood flows merge into a narrow channel to create resistance
and control the lumen pressure at the collagen site corresponding to (P2+P1)/2. The
pressure readings in these locations allowed the pressure drop across the collagen to be
controlled, thus allowing computer simulation (Figure 3-1B) of Darcy flow through the
complex geometry assuming constant permeability of the collagen (Figure 3-1C).
Exposing a 250 µm long x 60 µm wide surface area of collagen (± linked lipidated tissue
factor) to whole blood flow provided a localized thrombotic site comparable to a previous
device without permeation [31]. The side view of collagen made it possible to image the
permeation of dyes and the morphology of fibrin and platelet deposits as they contracted
(Figure 3-1D and Figure 3-1E).
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Figure 3-2

A microfluidic device to control transthrombus pressure drop
independent of shear rate.

Syringe pump 1 and syringe pump 2 are constant volume pumps that perfuse anticoagulated whole blood and 5 mM Ca2+ buffer respectively. The increased downstream
resistance due to a narrowed length of channel and the buffer flow causes an increase in
upstream pressure. The pressure measurements at P1, P2, and P3 are converted from
voltages to digital signals which LabVIEW records and uses to proportionately control
pressure drop via an increase or decrease in syringe pump 2 flow rate.
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3.3.2 Stopping flow caused platelet and clot retraction
During permeability testing of platelet deposits (no thrombin), the interruption of
blood flow resulted in a drastic contractile response of the newly formed clot (Figure
3-3). This retraction unexpectedly enhanced permeability due to the reconfiguration of
the supporting collagen and opening of flow paths along the sides of the collagen (Figure
3-4). To investigate the contraction triggered by flow cessation, platelet deposits were
formed for 10 min with embedded 50 nm fluorescent beads as fiduciary markers (inlet
wall shear rate of 1130 s-1). A wall shear rate of 1160 s-1 was used to reproduce rates
found in capillaries where the pressure drops between the vessel lumen and interstitial
space are known [25, 26]. This shear rate is also in the range of arterial flows. Following
the thrombus formation for 10 min, the flow was switched without interruption to buffer
for 4.5 min and then flow was completely stopped. Switching the flow from blood to
buffer prevented the arrival of new platelets and release of fresh ADP or TXA2 [66, 67].
Thrombus structure was mapped before and after stopping the flow (Figure 3-3A). The
upstream and downstream edge contraction rates were measured throughout the buffer
flow period and after flow stoppage (Figure 3-3B). Contraction rates 1 to 2 min after
flow cessation significantly increased by 6.5-fold (upstream region) and 4.6-fold
(downstream region) (P<0.05), compared to the rate during buffer flow. Donor to donor
variability (n=3 donors) for total clot contraction, 7 minutes after flow arrest, was 8.93 ±
3.89 μm and 13.6 ± 4.42 µm at the upstream and downstream positions respectively. The
restructuring of the thrombus upstream and downstream edges by 2 min post flow
cessation resulted in contractile trajectories of embedded beads towards the center of the
thrombus mass (Figure 3-3C and Figure 3-5C). Comparisons of the time dependent
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contraction data in the Y and Z direction at upstream and downstream positions of the
clot demonstrated increased contraction rates after flow cessation (Figure 3-3D).
Movement in the +Z-direction occurred rapidly and simultaneously in the upstream,
downstream and middle positions due to an immediate rebound effect caused by a
reduced pressure drop and reduced permeation when the flow was stopped (Figure 3-5).
Total bead distance in the Y and Z direction shows the rates at which the clot contracts in
all three locations (Figure 3-5). The ~1 min delay in contraction in the Y direction is one
indicator of an active signaling mechanism that must be engaged following the cessation
in flow.
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Figure 3-3

Flow arrest triggers clot contraction.

A thrombus formed in the absence of thrombin and presence of fluorescent 50 nm beads
was rinsed with Ca2+ buffer for 4.5 min before the cessation of flow caused a rapid
contraction. The outline of a pre-retracted thrombus (t’=-1 min) shows the inward
retraction of the thrombus following flow stoppage (t’=0 to 2 min) (A). Contraction rate
of the upstream and downstream sections of the thrombus were measured before and after
flow arrest (n=3 donors) (B). Trajectories of the 50 nm beads represent the contractile
response of the thrombus at upstream (red, n=6), middle (blue, n=3), and downstream
(green, n=6) locations (C). Stopping the flow caused a significant increase in contraction
rate in the Y and Z directions. To quantify these rates, the times before (0-2 min) and
after flow cessation (0-1 min, 1-2 min) were monitored for bead velocity in the three
sections of the thrombus (D). Downstream contraction rate in Y direction is shown as
absolute value for contraction toward the middle region. *, P<0.01; error bars indicate
mean ± SD.
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Figure 3-4

Clot permeability.

Thrombi formed under 1130 s-1 were pulsed with fluorescent dye at controlled pressure
drops. The normalized input and output fluorescent intensities, along with a numerically
predicted output from COMSOL were measured over time for clots formed in the
absence (A) and presence of TF (B). Thrombus formed without thrombin reduced the
residence time of the permeated dye by 30 s compared to platelet/fibrin thrombus.
COMSOL simulations were used to numerically calculate permeability over collagen
(n=9), platelet (n=6, 5 donors), platelet/fibrin (n=4, 4 donors), and platelet/flow
interrupted (n=2, 2 donors) geometries at constant pressure drops (C). †, P<0.01; error
bars indicate mean ± SD.
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Figure 3-5

Spatiotemporal variation of contraction with flow arrest.

Platelet deposits with 50 nm beads were formed at 1130 s-1 and ΔP=23.5 mm Hg.
Deposits were rinsed with buffer 4.5 min prior to flow arrest. Total bead distance was
measured before and after flow cessation at the upstream, middle and downstream
positions within the clot, in both the Y (A), and Z directions (B). The fastest velocity of
beads travelling in the Y direction was ~1 min following flow arrest. Conversely, the
immediate decrease in pressure drop and clot permeation caused the bead distance in the
Z direction to immediately increase after the cessation of flow. Bead trajectories were
mapped in the upstream (red), middle (blue) and downstream (green) portions of the clot
throughout the duration of the experiment (C).
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3.3.3 Permeability of collagen, platelet deposits, and platelet-fibrin thrombus
without flow interruption
To measure permeability without triggered thrombus contraction, dye tracer was
pulsed immediately following whole blood flow without interruption of the flow. Inlet
and outlet concentrations were measured with time to determine the permeation velocity
at several physiologic pressure drops [25, 26]. Permeability was numerically calculated
over the complex geometry (Figure 3-4A and Figure 3-4B) by reducing the squared
error between the experimental and simulation permeation velocity. We validated this
approach by comparing our calculated collagen permeability (κcollagen = 1.98x10-11 ±
0.640x10-11 cm2) with previous literature values (Figure 3-4C) [41, 42].

Similarly,

permeation velocity was measured across platelet deposits and platelet-fibrin thrombi
formed on collagen or TF/collagen scaffolds, respectively. Simulations that accurately
predicted the experimentally measured output of dye concentration over the course of
these experiments allowed determination of the permeability of the thrombus (Figure
3-4A and Figure 3-4B). The resulting permeabilities for platelet deposits (κplatelet =
5.45x10-14 ± 0.898x10-14 cm2) and platelet-fibrin thrombus (κthrombus = 2.71x10-14 ±
0.377x10-14 cm2) formed after 10 min of flow quantify the resistance that each structure
provides to resist bleeding. In the absence of thrombin, PPACK-treated whole blood
formed a platelet mass that was >350-fold less permeable than collagen alone. The
presence of thrombin and formation of fibrin provided a further 50% reduction in
permeability under hemodynamic conditions. Comparing the measured platelet deposit
permeability (without flow interruption) to that obtained following flow interruption
(κinterrupted = 2.91x10-13 ± 0.745x10-13 cm2) demonstrated the impact that stopping the flow
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had on the ability of the platelet deposit to maintain hemostasis in our device. In addition
to permeability measurements, we observed decreased platelet accumulation with
increased pressure drop (13.8 vs. 23.4 mm Hg) across the intraluminal thrombus in
PPACK-treated whole blood (Figure 3-6), likely due to increased transthrombus
permeation of ADP and TXA2 into the collagen.
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Figure 3-6

Transthrombus pressure drop affects platelet deposition.

PPACK-treated whole blood was perfused over a permeable scaffold of collagen at 1130
s-1 for 10 min. Platelet fluorescence intensity was measured for the platelet deposits
formed at a low (ΔP=13.8 mm Hg, n=3) and high (ΔP=23.4 mm Hg, n=3) pressure drops.
Increased transthrombus pressure drops caused a significant decrease in platelet
deposition at the site of injury. Data was collected using 5 separate donors; error bars
indicate mean ± SD.

62

3.3.4 Clot retraction in a rigid wall flow device with flow reduction or cessation
Clot retraction was also examined in a rigid, impermeable parallel-plate
microfluidic device lacking transthrombus permeation. Clot development in PPACKtreated whole blood was imaged on a 250 µm x 250 µm area of glass-supported fibrillar
collagen at an initial wall shear rate of 1160 s-1. Flow cessation resulted in a ~10 µm
contraction (upstream region) towards the center of the thrombus as outlined in Figure
3-7A.

In comparison, by switching to 10 µM blebbistatin perfusion (without flow

disruption) for 7 min before the flow cessation, clot retraction after flow cessation was
reduced 90% to only ~1 µm (Figure 3-7B). Blebbistatin is a well established platelet
myosin IIA ATPase inhibitor [68]. In a scenario where flow was reduced from arterial
(2000 s-1) to venous (100 s-1) shear rates, total contraction was similar to that observed
with flow cessation. Also, the contraction was ~5 µm larger than stopping the flow
following blebbistatin treatment (Figure 3-8). This result demonstrates the requirement
of platelet myosin IIA activity in the triggered thrombus contraction following flow
reduction or cessation.
We also measured clot retraction while stopping and restarting flow after a 30-sec
or 1-min interruption (Figure 3-7C). Statistical differences between complete cessation
of blood or buffer and the 30-sec flow interruption became apparent after 1 min.
Interrupting flow for 1 min took 5 min to diverge statistically from complete flow
cessation in buffer. While neither of the temporary flow interruptions (30-sec or 1-min)
were statistically different from each other, the longer 1-min delay provided enough time
to engage the contraction mechanism before eventually being diminished by the return of
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flow. The technique of switching to a non-physiologic buffer and measuring contraction
was validated by showing no contractile differences between stopping the flow in blood
or stopping buffer flow after 7 min of rinsing.
Since flow cessation results in a dramatic change in both wall shear stress and
wall shear rate on the thrombus structure, we investigated the role of soluble autocrine
mediators whose concentration may change when flow is stopped. To explore the role of
TXA2, we added 1 µM SQ-29,548, a potent TXA2 receptor antagonist [69]. Additionally,
the contribution of ADP was investigated by adding 10 µM MRS-2179 and 50 µM 2MeSAMP, selective inhibitors of the P2Y1 and P2Y12 platelet receptors, respectively
[70]. The dose response curves for these inhibitors have been well established and the
final concentrations used under flow exceeded the experimentally determined IC50
values to ensure complete inhibition [69, 70]. After 7 min of buffer/antagonist perfusion,
flow was stopped and total contraction was measured with time (Figure 3-7D). Both
antagonists significantly reduced the total clot contraction as compared to buffer. ADP
antagonists had the largest effect, reducing the total contraction nearly 75% over 7 min,
whereas TXA2 antagonist reduced the contraction by 44%. While uninhibited contraction
can vary significantly between donors (~32-44%), the addition of antagonist results in
consistent donor to donor percent reductions that vary <7% for ADP and <3% for TXA2.
These findings demonstrate ADP (from dense granules) and TXA2 from activated
cyclooxygenase-1 (COX1) were the mediators of the triggered contraction response upon
flow cessation.
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Figure 3-7

Contraction after flow arrest requires myosin and released
ADP/TXA2.

A parallel channel microfluidic device was used to develop thrombus in PPACK, at 1160
s-1. Following the formation of stable thrombi, Ca2+ or antagonist buffer was used to
rinse the surface for 7 min before stopping flow. Upstream contractions were observed in
five sections (blue dashed line) over ten min. Stopping flow without a buffer rinse (A)
and with a 10 µM blebbistatin rinse (B) show clot retraction compared to a trace (pink
line) before flow cessation. Total clot contraction measured over time compares the
effects of blebbistatin and intermediate flow stopping with stopping flow with and
without a buffer rinse (C). TXA2 and ADP antagonist significantly reduced total
contraction after flow cessation as compared to buffer (D). n=3 events at 5 discrete points
for each time-point indicated, using 5 separate donors; error bars indicate mean ± SD.
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Figure 3-8

Platelet flow sensing occurs when arterial flow is reduced to venous
flow.

A parallel channel microfluidic device was used to perfuse PPACK whole blood with
labeled platelets over patterned collagen at an initial wall shear rate of 2000 s-1. Arterial
shear rates were reduced to 100 s-1 (venous) following the deposition of labeled platelets
at the site of injury. Total contraction of the platelet deposits for three donors (n=7 total
events) were followed immediately after the reduction in shear rate. Significant
contraction was observed and can be compared to stopping flow following blebbistatin
treatment (n=3). Error bars represent mean ± SD.
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3.3.5 Intracellular calcium mobilization is triggered by ADP and TXA2 after flow
cessation
To explore the role of ADP and TXA2 in the flow sensing by the thrombus, we
loaded platelets in PPACK-treated whole blood with Ca2+ sensitive dye fluo-4. Prior to
flow cessation, we treated the platelet deposits with buffer in the presence and absence of
a triple cocktail of 1 µM SQ-29,548, 10 µM MRS-2179, and 50 µM 2-MeSAMP. To
minimize the measured intracellular Ca2+ fluctuations prior to flow cessation, initial
contraction measurements were made 3 min after treatment and 3 min before flow arrest.
The calcium signal increased as the platelet mass accumulated on the collagen between 0
and 4 min. When flow was switched to buffer at 4 min, there was no further deposition
of platelets resulting in a slight decrease in signal. In the absence of inhibitors, flow
cessation at 10 min caused an immediate and substantial mobilization of intracellular
calcium (Figure 3-9A) that was completely blocked by the triple inhibitor cocktail to
antagonize ADP and TXA2 (Figure 3-9B). The calcium mobilization occurred within
seconds following flow cessation and preceded the maximum platelet contraction rate
which began 1 to 2 min after flow stoppage (Figure 3-10).
The triggered contraction by the platelet mass, following flow cessation, is an
active material response requiring myosin (Figure 3-7C) and represents a flow sensing
mechanism to impede contraction when flow is present. ADP and TXA2 are the soluble
mediators responsible for this response (Figure 3-7D and Figure 3-9B). Both of these
agonists are highly sensitive to convective dilution which controls their concentrations in
the boundary layer around the thrombus [51]. Since soluble species mediated Ca2+
mobilization and contraction upon flow cessation, the flow sensing involved a transport
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mechanism: flow dilutes soluble species and flow cessation allows a rapid accumulation
of autocrinic ADP and TXA2 to trigger Gq signaling via platelet P2Y1, P2Y12, and TP
receptors (Figure 3-9C).
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Figure 3-9

Flow cessation triggers platelet intracellular calcium mobilization via
ADP/TXA2 autocrine signaling.

Platelets in PPACK whole blood were loaded with Ca2+ dye and perfused over collagen
at 1160 s-1. Following thrombus formation, whole blood perfusion was switched to Ca2+
or antagonist buffer for six minutes prior to stopping flow. Intracellular Ca2+ was
measured via fluorescent intensity over time for either a Ca2+ buffer (A) or ADP and
TXA2 antagonist rinse (B). n=3 events using 2 donors, error bars indicate mean ± SD. A
schematic illustrates the flow sensing ability of platelets via convective removal of
ADP/TXA2 (C). Shear () acting on the exterior of aggregated platelets accompanied by
the strain placed on interconnected αIIbβ3 may signal the inhibition of contraction or dense
granule (δ) release.
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Figure 3-10

Treating platelet deposits with ADP and TXA2 antagonist caused a
significant decrease in contraction rate following the cessation of flow.

Platelet deposits were formed on patterned fibrillar collagen in rigid wall, parallel
channel flow devices at 1160 s-1. Following platelet clot development, PPACK blood
flow was continuously switched to buffer (5 mM Ca2+, n=3), 10 µM MRS-2179 and 50
µM 2-MeSAMP (ADP antagonist, n=3), or 1 µM SQ-29,548 (TXA2 antagonist, n=3) for
7 min. Flow was stopped and contraction rates were measured before and after. Data
was collected using 1 donor and each independent event was analyzed at 5 discrete
points; error bars indicate mean ± SD.
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3.4 Discussion
We report a novel hemodynamic sensing function of intraluminal blood clots.
Flow impedes clot retraction. When flow stops, intraluminal clots retract more rapidly
and to a greater extent. This hemodynamic sensing by platelets in thrombus involves a
rapid mobilization of calcium that strictly requires released ADP and TXA2. Myosin
activity is also required for the triggered contraction upon flow cessation, indicating that
the contraction is not a passive material response to reduced drag forces. This concept of
a triggered, active response is also consistent with the ~1 min delay between flow
cessation and enhanced contraction.
While platelet contraction of a clot is usually considered in an isotropic context
where blood is clotted in a tube and then detached from the glass walls to allow
contraction, intraluminal thrombus formation is fundamentally different. In an isotropic
assay, platelets have random orientation within a fibrin network whereas platelets
depositing under flow conditions spread on collagen and then form many more plateletplatelet interactions due to high platelet concentration in the thrombus. In the thrombus
formed under flow, the structure is less isotropic and spread platelets would be expected
to exert greater forces along their axis of spreading and lesser forces perpendicular to the
plane of spreading. Furthermore, clotted whole blood in a tube contains incompressible
red blood cells at the prevailing hematocrit, while thrombus formed under arterial flow
are greatly enriched in platelets (50-100X platelet rich plasma levels) and substantially
depleted of RBC.
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Despite recent advances in microfluidic devices and intravital mouse microscopy,
few tools are available to control and study the effects of thrombus permeation under
flow conditions.

Recent studies examining angiogenesis demonstrated microfluidic

devices that hold promise for studying in vitro clot permeability under flow conditions
[36, 41]. However, these designs lacked the potential to produce controllable pressure
drops and shear rates relevant to thrombosis and hemostasis. In the present study, we
designed a microfluidic device to develop whole blood clots under physiologic flow and
to investigate transthrombus permeation in the presence of a controlled pressure drop.
The microfluidic device allowed the first reported in vitro clot permeability for clots
formed under flow. While a measurement for the permeability of a contracted clot could
not be obtained due to the accompanied structural changes in the absence of endothelium,
it is expected to be less than that of a non-retracted platelet-fibrin deposit.

Our

measurement for these deposits represents a quantitatively important upper bound of the
contracted clot permeability and the associated inner clot transport of ADP and TXA2.
Interestingly, the permeability of healthy rabbit aortic wall is on the order of 10 -14 cm2
[54], which is quite similar to our measurement of a platelet-fibrin thrombus. This
suggests that a platelet-rich intraluminal thrombus has a permeability that is well matched
to the surrounding intact endothelium.

In addition to matching rigidity [59], an

intraluminal thrombus may match permeability to the surrounding vessel wall. Under
flow conditions, we propose flow sensing helps the spread platelet(s) maintain hemostatic
function by balancing the contractile apparatus with the applied flow to limit platelet
contraction since contraction would potentially create gaps for leakage or alter nearby
endothelial function.
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In a quantitatively more intense example of hemostasis, a blunt impact that
compresses a vessel without rupturing the vessel would be expected to cause more
extensive endothelial denudation.

This situation is perhaps most analogous to the

experimental configuration developed in this study. When blood flow is maintained in
such an injured vessel, the flow impedes clot contraction because wound closure would
not be needed. Also occlusion might be prevented since clot stabilization via contraction
is impeded by flow. Reduced ADP/TXA2 transport may also facilitate the formation of a
dense inner thrombus core [71], while the outer domains of the clot remain loose and
friable due to flow sensing. Throughout our studies with multiple donors, this was
repeatedly verified by the constant but relatively low contraction rate under flow (Figure
3-3B and Figure 3-11). As vessel injury becomes severe enough to cause vessel rupture
with blood leaving the vascular space, blood pools around the puncture/rupture/severed
site. This results in more isotropic clotting of whole blood, which can exert isotropic
contraction on the surrounding tissue to facilitate wound closure and consequently
hemostasis (Figure 3-12). In this situation, the pooled blood around a leaking vessel is
not subjected to substantial hemodynamic flow to dilute ADP/TXA2 and thus impair
platelet actinomyosin-mediated contraction.

Additional highly diffusible platelet

activators may also play a role in this observed contraction and provide an area of future
study.
To further investigate the novel flow sensing abilities of platelets we examined
their ability to contract following 30 seconds or 1 minute interruptions in flow.
Contraction rates initially followed previous experiments but were drastically dampened
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upon the return of flow (Figure 3-13). This result suggests that the quasi-steady state
that platelet deposits reach under hemodynamic forces preserves their ability to rapidly
contract in response to flow arrest. Flow sensing by a thrombus balances the need for
wound closure and hemostasis against the risk of intraluminal occlusive thrombosis with
dense contracted and lytic-resistant structures [72]. In cases of normal hemostasis, this
mechanism would allow clots to contract gradually from their interior towards their
exterior as hemodynamic flow is reduced. The extent to which stress present in the
thrombus plays a role in signaling (i.e. mechanotransduction) remains a subject of future
study. These experiments clearly demonstrate the ability of platelet deposits to rapidly
assemble into a hemodynamic sensor and contract upon the arrest of flow.
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Figure 3-11

Blebbistatin, a myosin IIA inhibitor, reduced contraction rates before
and after flow cessation.

Whole blood anti-coagulated with PPACK was perfused at 1160 s-1 over impermeable
collagen in a parallel channel flow device. Flow was stopped immediately (blood, n=3)
or following a 7 min rinse with 5 mM Ca2+ buffer (n=3) or 10 µM blebbistatin (n=3).
Rinsing platelet deposits with buffer for 7 min was not significantly different than a
physiological flow arrest in blood. Data was collected using 2 separate donors and each
independent event was analyzed at 5 discrete points; error bars indicate mean ± SD.
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Figure 3-12

Platelet contraction is dependent on local hemodynamic flow
conditions.

For blood clotted under static conditions platelets can exert isotropic contraction (A).
When platelets spread on a surface, contraction becomes anisotropic due to platelet
morphology (B). When non-occlusive intraluminal thrombi form at sites of plaque
rupture (C) or denuded endothelium (D), contraction is limited due to the thrombus flow
sensing where autocrine agents are controlled by convective transport. However,
punctured (E) or severed (F) vessels, where flow is substantially decelerated, allows
isotropic contraction of platelets and surrounding tissue to securely close the wound.
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Figure 3-13

Reestablished flow dampens contraction mediated by temporary flow
interruption.

Parallel flow channels were used to form platelet deposits in PPACK whole blood at
1160 s-1. Following the development of the deposits, flow was continuously switched to
buffer for 7 min. Immediately following the rinse, flow was interrupted and resumed
after 30-sec (n=3) or 1-min (n=3). There were no significant differences in the
contraction rates between the two interruption times due to the reestablished
hemodynamic flow conditions. Data was collected using 1 donor and each independent
event was analyzed at 5 discrete points; error bars indicate mean ± SD.
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Chapter 4 : Fibrin, ’-fibrinogen, and trans-clot pressure gradient control
hemostatic clot growth during human blood flow over a collagen/tissue factor
wound
4.1 Introduction
During hemostasis, stable clot formation at the site of wounding is facilitated by
the growth of a platelet plug and the generation of fibrin. Essential to vascular integrity,
this structure must form rapidly under flow at an injury site, withstand hemodynamic
forces, and prevent pressure-driven blood loss. With the laser injury mouse model, the in
vivo architecture of the hemostatic clot has been revealed to contain two distinct regions
of platelet activation: an inner tightly packed ‘core’ with extensive α-granule release and
an unstable outer ‘shell’ with minimal α-granule release [27].

α-granule release is

identified by P-selectin display and is characteristic of the core. Recent mouse studies
have shown that the core region is thrombin and fibrin rich, platelet-retracted with lower
porosity and reduced albumin mobility, and localized to the interior of the clot closest to
the injury site. In contrast, the shell region is thrombin and fibrin poor, more porous and
localized to the exterior of the clot towards the vessel lumen, and displays significant
platelet turnover [27, 73-75].
The regional heterogeneity of platelet activation in clots highlights the
complexities of when and where agonists are localized and what biochemical and
physical parameters regulate hemostatic clot development. Importantly, the factors that
trigger wall-attached clots to become fully occlusive thrombi are not fully understood,
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but may include platelet hyper-reactivity, dysregulated thrombin production, and
enhanced vWF function in pathological stenotic flows [76-78].
Thrombin is a potent platelet activator at ~1 nM and cleaves fibrinogen to drive
fibrin polymerization at ~10 nM or higher. In humans, the -chain of fibrinogen has two
expression variants: A (main form) and ’ (splice variant). The ’-chain contains a 20amino acid extension due to alternative mRNA splicing [79]. Unique to ’-fibrinogen is a
high affinity binding site for exosite II on thrombin [80]. While A/’ fibrinogen only
makes up about 8-15% of total fibrinogen, ’-fibrinogen can serve as a sink for locally
produced thrombin [81-83]. Also, Factor XIII has a 20-fold higher affinity for the A/’
fibrinogen heterodimer than the A/A fibrinogen homodimer [84].
Using microfluidics and human blood, our prior studies have demonstrated that
fibrin polymerization stabilizes clots by anchoring the clot to the injury site with ~12 to
28-fold greater resistance to shear forces [48]. Our goal was to study the impact of
fibrin(ogen)’s antithrombin properties and fibrin polymerization on thrombin mediated
clot growth in human blood. Mouse models do not allow precise control of: prevailing
shear rates, trans-thrombus pressure drops, or biochemical constituents of the wound.
Additionally, mice lack the ’ splice variant of fibrinogen [85].

In order to study

fibrin(ogen)’s role in the hemostatic growth of thrombi, it was critical to have
reproducible hemodynamics. There are few studies that demonstrate the ability to
simultaneously measure and control wall shear rate and trans-clot pressure gradients
(ΔP). This limitation motivated our previous work on designing a microfluidic device
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capable of independently controlling both wall shear rate and ΔP [46, 86]. Using this
device we have now studied the localization of thrombin, the role of thrombin in platelet
P-selectin display, and the role of fibrin polymerization and ’-fibrinogen in regulating
fibrin function. We report that fibrin, in addition to stabilizing clot structures against
shear forces [48], is critical in localizing and restricting thrombin to the core region of a
hemostatic clot.
4.2 Materials and Methods
4.2.1 Materials
The following instrumentation and reagents were used:

analog pressure

transducers (Honeywell Sensing and Control); human type-1 monomeric collagen
(VitroCol, 3 mg/ml) (Advanced Biomatrix); recombinant tissue factor (Dade® Innovin®;
Siemens); Sigmacote® (Sigma-Aldrich); polydimethylsiloxane (PDMS) (Ellsworth
Adhesives); anti-fibrin antibody (gift from M. Poncz, Children’s Hospital of
Philadelphia); anti-fibrinogen ’ antibody (clone 2.G2.H9) and H-Gly-Pro-Arg-Pro-OH
(GPRP, EMD Millipore); peak 1 fibrinogen (XIII free) and peak 2 fibrinogen (Enzyme
Research Laboratories); anti-human CD62P antibody (BD Biosciences); anti-human
CD41 antibody (AbD Serotec); anti-human CD32 antibody (STEMCELL Technologies
Inc.); Boc-VPR-AMC fluorogenic peptide substrate (R&D Systems®).
4.2.2 Blood Collection
All blood donations were conducted in accordance with the IRB at the University
of Pennsylvania. Human blood was drawn via venipuncture from healthy volunteers
reported as both alcohol and medication free. Studies conducted in the presence of
80

thrombin were completed with blood drawn directly into 40 µg/ml corn trypsin inhibitor
(CTI, Haematologic Technologies Inc.). Thrombin free investigations were performed
with blood anticoagulated with 40 µg/ml CTI, 100 µM Phe-Pro-Arg-chloromethylketone
(PPACK, Haematologic Technologies Inc.), and 1 µM Apixaban (Selleck Chemicals,
Houston, TX, USA). Platelets were labelled with a fluorescently conjugated anti-CD41
monoclonal antibody (1 μg/ml, Abd Serotec) and P-selectin was labelled with a PEconjugated anti-CD62P antibody (0.0625 μg/ml, Becton Dickinson Biosciences).
Thrombin localization was visualized using either 5 µM Boc-VPR AMC or a thrombin
sensitive antibody (5 µg/ml, ThS-Ab) [43]. Fibrin studies were performed with 0.5 µg/ml
of a fluorescently conjugated, fibrin specific antibody (gift from the M. Poncz lab,
Children’s Hospital of Philadelphia) [44, 45].
4.2.3 Microfluidic device for control of wall shear rate and trans-clot ΔP
The microfluidic device fabrication has previously been described [38]. In brief,
negative photoresist (KMPR 1050, MicroChem Corp.) was patterned on silicon wafers
(D=100 mm, WRS Materials) using photolithography techniques. Soft lithography was
then used to fabricate polydimethylsiloxane (PDMS) devices from the patterned wafers.
The devices were designed with two inlets, two outlets, a post scaffold region and three
pressure ports. Holes for tubing (0.020” ID x 0.060” OD, Cole-Parmer) and blunt
needles (Small Parts) were punched with 0.75 and 0.5 mm I.D. corers (Harris UniCoreTM, Ted Pella, Inc.) The main channel was comprised of two pressure ports, one
upstream and one downstream of the post scaffold region. These pressure ports were
used to load the post scaffold region with polymerized type I collagen ± tissue factor (TF)
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following treatment with 10% bovine serum albumin (BSA). Scaffold loading was
accomplished by pulling the collagen solution through the main channel pressure ports
out through the scaffold outlet. The entire channel was immediately rinsed following
scaffold loading to remove any remaining fibers outside of the scaffold.

After the

channels were rinsed and loaded, the three pressure ports (main channel upstream, main
channel downstream, and scaffold exit) were hooked up to pressure transducers
(Honeywell Sensing and Control). The main channel inlet was connected to a whole
blood syringe that was perfused by a constant volume syringe pump (PHD Ultra, Harvard
Apparatus). The downstream inlet was connected to a buffer syringe that was perfused
by a controlled constant volume syringe pump (PHD 2000, Harvard Apparatus). The
buffer pump was controlled via a PID controller designed in LabVIEW (National
Instruments). Briefly, the controller maintains constant channel pressure by reading
channel pressure measurements (NI USB-6210, National Instruments) and adjusting the
buffer pump flow rate. PID settings were calculated using the Ziegler-Nichols tuning
method. These settings facilitated simultaneous control over multiple channels (Figure
4-1).
Devices were set up on an inverted microscope (IX81, Olympus America Inc.)
with a three slide holder. Anticoagulated whole blood perfused through the channel at a
constant wall shear rate was labelled with fluorescent antibodies for imaging using a
CCD camera (ORCA-ER, Hamamatsu). Clots were imaged from a side view prospective
as they developed on the localized collagen ± TF scaffold. Unique to this design is the
ability to independently control both the inlet flow rate (wall shear rate) and the
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transthrombus pressure gradient (ΔP) as the clots developed. Wall shear rates ranged
from a venous shear rate of 100 s-1 to an arterial shear rate of 2000 s-1 [23]. All
transthrombus pressure gradients were maintained within a physiologically relevant range
(ΔP=9-30 mm Hg) [25, 26].
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Figure 4-1

Independent pressure control was achieved in three channels
simultaneously.

Dynamic pressure measurements were made using 0-1 psig pressure sensors at a constant
wall shear rate. All three channel pressures were controlled within 2.5% tolerance (A).
PID control was used based off of the average of all channels and was maintained within
a 1% tolerance of the set point (B).
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4.2.4 Fibrin polymerization and ’ fibrin(ogen) inhibition
Studies investigating fibrin polymerization were completed with GPRP. Whole
blood anticoagulated with CTI or CTI/PPACK/Apixaban was incubated with HEPES (4(2-hydroxyethyl)-1-piperazineethanesulfonic acid)-buffered saline (HBS) or 5 mM GPRP
for 5 min. Two channels were then perfused simultaneously with the control (HBS) and
5 mM GPRP whole blood samples. Both channels maintained a constant wall shear rate
(100 s-1, 400 s-1, or 2000 s-1) and ΔP (20 mm Hg).
An anti-human CD32 antibody and an anti-fibrinogen ’ antibody were both used
to investigate ’ fibrin(ogen)’s role in thrombin regulation. CTI whole blood was labelled
with platelet, P-selectin, thrombin, and FcγRII antibodies for 5 min. Antibodies specific
for FcγRII were used to prevent CD32-mediated platelet activation following incubation
with anti-fibrinogen ’ antibodies. Fibrinogen ’ antibody free control buffer (0.1M Trisglycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide, 30% glycerol) was added to one
sample and anti-fibrinogen ’ antibody was added at a 1:1 molar ratio with ’ fibrin(ogen)
(0.3 mg/ml) [87]. Following 5 min, four channels were perfused simultaneously at a
constant ΔP (16 mm Hg). Two channels were perfused at 100 s-1 and the other two were
perfused at 2000 s-1, both shear rates had one buffer control sample and one ’
fibrin(ogen) antibody sample.
4.2.5 Mouse cremaster arteriole laser injury model
Male mice 8-12 weeks of age were anesthetized with an intraperitoneal injection
of sodium pentobarbital (90 mg/kg), and their jugular vein was cannulated for the
introduction of fluorescent biomarkers. The mouse cremaster was exposed, cleaned of
85

connective tissue, opened, and prepared for viewing by intravital microscopy.

The

cremaster was maintained under a constant flow of bicarbonate buffer (37 C) bubbled
with 95%/5% N2/CO2. Mouse arterioles of 30-50 μm diameter were visualized with a
BX61WI microscope (Olympus, St. Louis, MO, USA) with a 60X (0.9 NA) water
immersion objective, and a CSU-X1 spinning disk confocal scanner (Yokogawa, Sugar
Land, TX, USA). Fluorescence imaging was done using diode pumped solid state lasers
(405 nm, 488 nm, 561 nm, 647 nm) with AOTF control as an excitation source
(LaserStack, Intelligent Imaging Innovations, Denver, CO, USA), and images were
captured using an Evolve digital camera (Photometrics, Tucson, AZ, USA). Endothelial
cell ablation was performed with a pulsed nitrogen dye laser (SRS NL100, 440 nm)
focused on the vessel wall through the microscope objective.

The laser was fired

between 1-10 times until red blood cells either escaped into the extravascular space or
became trapped within the layers of the vessel wall. The University of Pennsylvania
Institutional Animal Care and Use Committee approved all procedures. Platelets and Pselectin were labeled with fluorescent antiGermany, Clone: Xia.C3) and anti-CD62P respectively. Thrombin activity was measured
using the previously described mouse thrombin sensor antibody (mThS-Ab). These
fluorescent markers were imaged once per second for 3 minutes.

Background

fluorescence was measured within the vessel and subtracted from the images to determine
staining intensities.
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4.2.6 Image processing
Raw image stacks were processed by ImageJ (NIH). All stacks were background
corrected using the “Subtract Background” feature in ImageJ. This feature averages the
background over domains using a rolling ball approach [88]. Following background
correction, images were thresholded using the triangle method [89, 90]. Binary images
were then cropped to the middle 68% (first post to last post) of the clots while retaining
the entire clot width. Total area was calculated for each frame and fluorescent tag.
4.2.7 Statistics
P values were calculated using paired or unpaired, two-tailed student’s t-tests.
Statistically significance was reported if P<0.05.
4.3 Results
4.3.1 Microfluidic device for investigating clot architecture at controlled wall shear
rates and transthrombus pressure gradients
Thrombi were developed in vitro using a microfluidic device (Figure 4-2A). Clot
formation was initiated when CTI whole blood was perfused across a post scaffold region
loaded with collagen/TF (Figure 4-2B). The architecture of the developing clot was
investigated from a side-view perspective at independently controlled wall shear rates
and trans-clot pressure gradients.

Clots formed within this microfluidic device, on

collagen/TF scaffolds demonstrated distinct P-selectin positive and negative areas
(Figure 4-2C). The P-selectin positive region (core) remained localized to the interior of
the clot, closest to the collagen/TF surface.

The P-selectin negative region (shell)

enclosed the interior core region and remained exposed to the flowing whole blood. We
have previously reported the ability of our device to generate these core/shell
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architectures, which have only been observed in vivo [27, 86]. Recently, thrombin was
revealed as the primary agonist responsible for core development in vivo during mouse
arteriole laser injury [27, 73-75]. These results align with investigations we made using
the soluble thrombin activity peptide, Boc-VPR-AMC where the highest thrombin
activity was localized to the core region (Figure 4-2D). This is the first report of
thrombin localization to the core region of human blood clots.
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Figure 4-2

Thrombus architecture was investigated in a microfluidic device
capable of independently controlling transthrombus pressure
gradients and wall shear rates.

Anticoagulated whole blood was perfused at a constant wall shear rate (Q1) while the
transthrombus pressure gradients (ΔP) were independently controlled via downstream
buffer infusion Q2 (A). Polymerized collagen ± TF was localized to a post scaffold
centered between pressure ports P2 and P1 (B). Spatial and temporal thrombus
development was monitored by side-view imaging at controlled wall shear rates and ΔP.
Platelet (red) and P-selectin (green) were imaged to investigate spatial differences in
platelet activation under physiologic flow conditions (C). A fluorogenic, thrombin
cleavable substrate Boc-VPR-AMC was added to whole blood to demonstrate localized
thrombin activity within clots developed in the presence of ΔP (D).
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4.3.2 Transthrombus pressure gradients influence thrombin mediated clot growth at
400 s-1
Thrombin mediated clot growth was investigated by perfusing CTI-treated whole
blood over a collagen/TF scaffold at 400 s-1. Transthrombus pressure gradients were
maintained at either a low (9.0 mm Hg) or high ΔP (29.4 mm Hg). Total platelet area
was calculated at each time point over the duration of the experiment (t=10.8 min). Clots
developing at lower ΔP (9.0 mm Hg) experienced faster initial growth (~3.8 fold faster,
t=0-1.8 min, P<0.05) and larger final heights (~1.5 fold larger, t=10.5 min, P<0.025) than
clots experiencing higher ΔP (29.4 mm Hg) (Figure 4-3A). The P-selectin (core) area
was 57% of the total clot area for both low and high ΔP (Figure 4-3B). While % core
remained constant, final core area was reduced by 33% (P<0.05) when ΔP was increased.
Similar trends were observed when measurements were made with a thrombin sensing
antibody. Final thrombin area was reduced by 43% (P<0.05) when ΔP was increased 3.2
fold (Figure 4-3C). This result indicates that the elution of inner clot thrombin to the
surface of the clot was met with opposition by pressure-driven permeation of fluid
through the clot, towards the “extravascular” space (the collagen post array). When
trans-clot pressure drops were increased, the permeation-mediated transport through the
clot also increased proportionately. This reduced thrombin transport towards the clot
surface to result in a smaller core area. Thrombin and P-selectin area were highly
correlated both spatially and temporally at low ΔP (R2=0.91) and high ΔP (R2=0.95)
(Figure 4-3D). Reducing the permeation by decreasing ΔP results in greater flux of
thrombin from the collagen/TF interface through the clot toward the lumen, thus resulting
in a larger P-selectin positive core at lower ΔP.
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Figure 4-3

Transthrombus pressure gradients reduce clot size by diminishing
thrombin boundary growth.

Platelet area was measured for clots (n=3) formed at a constant wall shear rate (400 s-1) in
the presence of either a low (ΔP=9.0 mm Hg) or high (ΔP=29.4 mm Hg) transthrombus
pressure gradient (A). Clot architecture was investigated by measuring intrathrombus Pselectin (B) and thrombin (C) area for each condition. The correlation between platelet
activation marker P-selectin and thrombin area were quantified for each condition over
the duration of the experiment (t=10.8 min) (D).
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4.3.3 Fibrin polymerization reduces both total platelet and core area at 400 s-1
Fibrin polymerization has been recognized as an important step in clot
stabilization and the prevention of embolic events [48]. Beyond this role, less is known
about what impact fibrin polymerization may have on clot architecture and regulation of
clot growth rate. In order to study these effects on thrombus growth and architecture we
added GPRP, a fibrin polymerization inhibitor. Whole blood anticoagulated with CTI
was incubated with and without GPRP prior to perfusion (400 s-1) over a collagen/TF
surface. All clots were developed in the presence of a constant transthrombus pressure
gradient (Control-ΔP = 20 ± 0.7 mm Hg, GPRP- ΔP= 20 ± 0.5 mm Hg). Thrombus
growth and architecture (P-selectin, fibrin) were monitored dynamically for 10.5 min of
perfusion. Total platelet area and clot height grew to a greater extent when fibrin
polymerization was inhibited by 5 mM GPRP (Figure 4-4A). Following 3 min of
growth, clots formed in the presence of polymerized fibrin were statistically smaller
(P<0.05) than clots formed without polymerized fibrin. Disparity between clot size
became even greater following 5.25 min (P<0.025). Final clot height (t=10.5 min) was
67% (P=4.95x10-5) larger when fibrin polymerization was inhibited.

Accompanying

total clot growth was an increase in core area (Figure 4-4B). P-selectin positive area
grew 2-fold larger (P=0.003) when fibrin polymerization was absent. As expected, fibrin
polymerization, as measured by a fibrin specific antibody, was completely abolished by 5
mM GPRP (Figure 4-4C). The growth of fibrin slightly preceded the P-selectin positive
core development in the control clots (no GPRP).

This indicated that fibrin

polymerization was responsible for mitigating core development and total clot growth at
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400 s-1, a phenomena that was not observed when thrombin was inhibited with PPACK
(Figure 4-5).
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Figure 4-4

Fibrin polymerization reduces clot growth at a wall shear rate of 400
s-1 and ΔP=20 mm Hg.

Platelet area (n=7, A) was measured in the absence (control) and presence (5 mM GPRP)
of fibrin polymerization inhibitor Gly-Pro-Arg-Pro at a constant transthrombus pressure
gradient (ΔP=20 mm Hg) and wall shear rate (400 s-1). P-selectin (n=7, B) and fibrin
(n=4, C) area were monitored for each condition during 10.5 min of CTI whole blood
perfusion.
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Figure 4-5

GPRP has no effect on the total clot or P-selectin (core) area when
thrombin is inhibited.

Whole blood perfused at 400 s-1 was treated with PPACK/Apixaban/CTI to prevent
thrombin generation and activity. Total clot and P-selectin (core) area were investigated
in the presence and absence of 5 mM GPRP.
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4.3.4 Wall shear rate does not influence the core or thrombin area but does
influence the role of fibrin
Since our device facilitated independent control of both wall shear rate and
transthrombus pressure gradients, we investigated clot architecture at constant ΔP (20
mm Hg) for three shear rates (100 s-1, 400 s-1, 2000 s-1) ranging from venous to arterial
flows. Total clot, core, thrombin and shell area were measured for 10.5 min of whole
blood perfusion. The final area (t=10.5 min) for each were reported at the three distinct
shear rates (Figure 4-6A). Interestingly, wall shear rate did not significantly alter the
core or thrombin area when the trans-clot ΔP was held constant at 20 mm Hg. The only
significant change that wall shear rate influenced was the shell size. The shell size was
greatest at a venous shear rate of 100 s-1 as compared to 400 s-1 (P=0.026) and 2000 s-1
(P=0.007). This increased shell thickness resulted in an increase in total clot size at 100
s-1 (P=0.009 for 400 s-1; P=0.015 for 2000 s-1). These outcomes indicated that shear rate
only influences shell size while the transthrombus pressure gradient influences both core
and thrombin boundary size (Figure 4-3 and Figure 4-6).
Clots in the presence of GPRP were developed in parallel with control clots for
each shear rate. The blockade of fibrin polymerization on total clot, core, thrombin, and
shell area was investigated at the final time point (t=10.5 min) (Figure 4-6B). Based on
our previous results at 400 s-1 (Figure 4-4), we expected GPRP blockade of fibrin
polymerization to enhance clot height and core area at both venous and arterial shear
rates. This expectation was confirmed for an arterial shear rate of 2000 s-1 (Figure
4-6C). The addition of GPRP significantly increased total clot area (1.45-fold for 400 s-1,
1.5-fold for 2000 s-1) due to a drastic increase in core area (2.0-fold for 400 s-1, 1.65-fold
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for 2000 s-1). The increase in core area was directly proportional to a significant increase
in thrombin area at both 400 s-1 (108% increase) and 2000 s-1 (87% increase).
Interestingly, clots developed at the venous shear rate of 100 s-1 did not increase in total
clot, core, or thrombin area when fibrin polymerization was inhibited with GPRP. These
results indicated that thrombin regulation in venous clots is not governed by fibrin
polymerization.
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Figure 4-6

Wall shear rate does not change the core or thrombin area but does
influence thrombin mediated clot growth in the absence of fibrin
polymerization.

Total, core (p-sel+), thrombin, and shell (p-sel-) areas were measured, at the final time
point (t=10.5 min), for clots developed at a constant pressure gradient (ΔP=20 mm Hg)
and varying wall shear rate (100 s-1, 400 s-1, 2000 s-1) (n=4 for each shear rate) (A). CTI
whole blood in the presence of 5 mM GPRP (fibrin polymerization inhibitor) was run in
parallel at all experimental conditions (n=4 for each shear rate) (B). The fold increase in
area with the addition of 5 mM GPRP was calculated for total, core, thrombin, and shell
area (C).
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4.3.5 ’ fibrin(ogen) reduces thrombin mediated clot growth at venous shear rates
but not arterial shear rates
In order to further investigate the role of fibrin(ogen) in venous and arterial clot
growth, we added a monoclonal ’-fibrinogen specific antibody to inhibit the high affinity
thrombin binding site on ’-fibrinogen (Figure 4-7). Antibodies were incubated in CTI
whole blood at a 1:1 molar ratio to 0.3 mg/ml ’ fibrinogen, a physiologically relevant
whole blood concentration [87]. Control and ’ antibody treated samples were perfused
simultaneously at both 100 s-1 and 2000 s-1. Total clot, core, and thrombin area were
measured dynamically at a constant trans-clot ΔP (control ΔP=15.5 mm Hg, ’ antibody
ΔP=15.7 mm Hg). Clots formed at the venous shear rate of 100 s-1 had significantly
increased total clot area, core area, and thrombin area when the high affinity thrombin
binding site on ’ fibrinogen was blocked (Figure 4-8, first column). Total clot area
after 11.25 min of whole blood perfusion was 2.0 fold larger (P=0.019) in the presence of
the ’ fibrinogen antibody. This increase in total clot area was associated with faster core
(1.5 min) and thrombin generation (1.25 min) and larger final areas (core-1.8 fold,
thrombin-1.6 fold). Conversely, there were no significant differences between thrombi
formed at the arterial shear rate of 2000 s-1 (Figure 4-8, second column).
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Figure 4-7

γ’-fibrinogen binds more thrombin and is inhibited to a greater extent
than γA-fibrinogen (free of the γ’-chain).

Wells in a 384 well plate were coated with either γ’-fibrinogen or γA-fibrinogen. After
rinsing and blocking non-coated surfaces with BSA, a monoclonal γ’-fibrinogen specific
antibody was added to half of the γ’-fibrinogen wells and half of the γA-fibrinogen wells.
Excess antibody was removed and thrombin was incubated in each well. Following
another rinse, a thrombin cleavable substrate (Boc-VPR-AMC) was added to each well
and cleavage was followed using spectrofluorometry.
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Figure 4-8

Inhibition of ’ fibrin(ogen) with a ’ specific monoclonal antibody
results in larger clots at venous but not arterial shear rates.

Whole blood anticoagulated with CTI ± ’ mAb was perfused over a collagen/TF scaffold
at a constant transthrombus pressure gradient (control ΔP=15.5 mm Hg, ’ antibody
ΔP=15.7 mm Hg). Total, core (p-sel+), and thrombin area were measured dynamically at
both venous (100 s-1, first column, n=3) and arterial (2000 s-1, second column, n=3)
shear rates throughout the duration of the experiment.
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4.3.6 Arterial shear rates promote increased platelet packing, greater thrombin
retention, and more fibrin generation per area than venous shear rates
Since clots formed at venous and arterial shear rates demonstrated inverse growth
patterns when fibrin polymerization or the high affinity thrombin binding site on ’
fibrinogen were blocked, we hypothesized that clot composition may influence
fibrin(ogen)’s role in thrombin regulation. We investigated platelet packing density
(Figure 4-9A), density corrected thrombin sensor cleavage (Figure 4-9B), and fibrin
packing density (Figure 4-9C) by comparing clots formed in CTI whole blood at 100 s-1
to those formed at 2000 s-1. Representative images at the final time point (t=11.5 min)
demonstrated increased platelet packing at 2000 s-1 as compared to 100 s-1. Likewise,
density corrected thrombin sensor cleavage and fibrin packing density were also
increased at arterial shear rates (2000 s-1) as compared to venous shear rates (100 s-1).
The fold increase in platelet packing density as measured by platelet fluorescence
intensity per area was on average 1.83 fold higher at 2000 s-1 than 100 s-1 (Figure 4-9D).
After normalizing the thrombin sensor fluorescence intensity for platelet density, the
results indicated that more sensor was cleaved in arterial clots than venous clots (1.4
fold).

This provides a lower estimate for the relative increase in thrombin activity in

arterial clots compared to venous clots. Supporting this estimate was the increased
generation of fibrin in arterial clots (2.36-fold). These results demonstrated a drastic and
important difference in the composition of clots formed at arterial or venous shear rates.
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Figure 4-9

Clots formed at arterial shear rates pack tighter, cleave more
thrombin sensitive peptide per area, and generate more fibrin per
area than venous clots.

CTI whole blood was perfused simultaneously at a venous shear rate of 100 s-1 and an
arterial shear rate of 2000 s-1. Platelet (A), normalized thrombin sensor (B), and fibrin
fluorescence intensity (C) were imaged for 11.5 min. The fold increase in platelet
fluorescence intensity per area (n=6) from clots formed at 100 s-1 compared to 2000 s-1
was averaged over the duration of the experiment (D). In addition, the density corrected
thrombin sensor cleavage (n=6) and fibrin fluorescence intensity (n=3) were calculated
and compared for venous and arterial clots.
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4.3.7 Fibrin polymerization reduces clot growth at pathological shear rates
In pathophysiology, wall shear rates can reach 100,000 s-1 in stenosed vessels
[24]. We investigated clot formation in a scenario similar to vessel stenosis by stepping
the wall shear rate up from an initial venous shear rate of 200 s-1 to a pathological shear
rate of 15,000 s-1. Clots were formed in PPACK whole blood at 200 s-1 for 7 min before
stepping the shear rate up to 15,000 s-1 for an additional 7.75 min (Figure 4-10A-C).
Following the increase to pathological shear rates, rapid platelet aggregation at the
upstream edge of the clot resulted in a low shear regime prior to the trailing edge of the
clot. The low shear regime facilitated the accumulation of ADP and TXA2 agonists.
This was evident by the clot contraction at the downstream edge of the clot (Figure
4-10C), a flow sensing mechanism that we previously documented when shear rates were
reduced [46]. In this experiment, the contraction towards the center of the clot was not
prevented, even at 15,000 s-1.
The role of fibrin polymerization was also investigated at pathological shear rates.
Whole blood anticoagulated with either CTI or PPACK was perfused across a
collagen/TF or collagen surface respectively.

Experiments were performed

simultaneously with both control and GPRP treated samples in order to evaluate the role
of fibrin polymerization. The blood was initially perfused at an arterial shear rate of 2000
s-1. After 5.4 min, the wall shear rate was increased to a pathological shear rate of 15,000
s-1 for the remaining 5.8 min of the experiment. The inhibition of fibrin polymerization
with GPRP in CTI whole blood resulted in increased clot growth for both arterial and
pathological shear rates (Figure 4-10D). The average clot height of GPRP clots was
104

73.2% larger after 5.4 min of flow at 2000 s-1 (P=0.006) and 152.4% larger after an
additional 5.8 min of flow at 15,000 s-1 (P=0.001). In contrast, PPACK whole blood
clots did not demonstrate a significant increase (P>0.05) with the addition of GPRP at
either arterial or pathological shear rates (Figure 4-10E). This demonstrated a specific
effect on clot growth due to the inhibition of fibrin polymerization and not off target
effects.
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Figure 4-10

Clot growth at pathological shear rates was abated by fibrin
polymerization.

PPACK whole blood was perfused across a collagen scaffold at 200 s-1. Clot formation
was imaged with a fluorescent platelet specific monoclonal antibody (red) (A).
Following 7 min of perfusion, the shear rate was increased to a pathological shear rate of
15,000 s-1. Images of clot formation were taken at t=10.75 min (B), and t=14.75 min (C).
Zones of low shear, caused by rapid platelet aggregation upstream, often formed and
contracted at the trailing edge of the developing clot. In a similar experiment either CTI
or PPACK whole blood was perfused over a collagen/TF or collagen surface
respectively. Perfusion was initially at 2000 s-1 prior to stepping the shear up to 15,000 s1
. Control conditions were compared to GPRP treated samples with inhibited fibrin
polymerization. Clot height was recorded throughout the duration of the experiment (D).
Average clot heights were calculated for both the control and GPRP samples. The
measurements were made for both CTI (n=4 each condition) and PPACK (n=4 each
condition) treated whole blood both before and after increasing the shear rate (E). (*,
P<0.01)
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4.4 Discussion
The clots developed in our device utilizing human blood (Figure 4-11A), closely
matched the architecture of clots developed in vivo (Figure 4-11B). When the device
was operated at a constant wall shear stress, we observed that transthrombus pressure
gradients could regulate the core and thrombin heights. Reducing transthrombus pressure
gradients resulted in an increase in the core and thrombin heights, leading to larger total
clot heights. In this scenario, pressure driven permeation through the clot towards the
extravascular space was reduced when ΔP was reduced. This decrease in permeation
toward the extravascular space allows for thrombin diffusion through the clot towards the
lumen. As the thrombin boundary grew, the core region grew. In turn, this may result in
an increase in ADP and TXA2 release as demonstrated by P-selectin exposure. Since
ADP and TXA2 are soluble small molecules and diffuse much faster than thrombin
(DADP=50x10-11 m2/s >> DThrombin=8x10-11 m2/s), they facilitated shell growth by
recruiting additional platelets to the surface of the clot (Figure 4-11C) [91, 92].
We demonstrated that the core/shell architecture was present throughout the
development of human blood clots under physiologic conditions of hemostasis over an ex
vivo wound of collagen/TF. The sensitivity of the core and shell development was
investigated by independently controlling the wall shear rate (100 s-1 to 2000 s-1) and
transthrombus pressure gradient (ΔP=9.0 to 29.4 mm Hg). Fibrin polymerization reduced
thrombin mediated clot growth at arterial but not venous shear rates.

This can be

explained by our observation of increased platelet and fibrin packing at arterial shear
rates as compared to venous shear rates. The influence of the shear rate on clot structure
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and composition became more evident when ’-fibrinogen’s high affinity thrombin
binding site was inhibited with a monoclonal antibody. When clots were developed at
venous shear rates (decreased packing density) and the high affinity thrombin binding site
on A/’ was inhibited, the size of the total clot, thrombin, and core increased.
We also demonstrated that the shell region is dependent on the local shear rate at
the surface of the clot whereas the core region is only a dependent on the transthrombus
pressure gradient. These results agree with the governing role of transport rates within
and around the developing clot. The low permeability of thrombi places an emphasis on
both convective and diffusive transport within the clot while the transport at the surface
of the clot is governed by the local wall shear rate (convection>>diffusion) [86]. This
means that thrombin, which has a much slower diffusion rate than ADP or TXA2,
requires the protection of the clot to effectively diffuse.

Conversely, the diffusive

transport rates of ADP and TXA2 are fast and can compete with larger convective forces
that are present near the surface of the clot. This is why shell growth has been directly
correlated with ADP and TXA2 [27]. So when surface convection rates are low, such as
venous shear rates, ADP and TXA2 diffusion plays a larger role in platelet recruitment.
This role is diminished at arterial shear rates which causes reduced shell growth. These
results define the physical parameters that govern clot development and the resulting core
and shell architecture of human clots.
Another important aspect of clot development is fibrin formation. In order to
study fibrin’s role, we examined the packing density of platelets and fibrin within human
thrombi formed at venous or arterial shear rates. We found that increasing the shear from
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a venous to an arterial rate results in an increase in both platelet and fibrin packing. We
also found an increase in thrombin activity at arterial shears. These results supported
previous work performed in vivo, which described the majority of fibrin formation as
being contained within the densely packed core [27, 73, 75]. Complementary in silico
investigations using the porosities of the tightly packed core and loosely packed shell
illustrated thrombin retention within the core region due to the lower porosity decreasing
the effective diffusion of thrombin [74].
To determine how fibrin contributes to the formation of a dense clot
microenvironment we formed clots in the presence of GPRP to prevent fibrin
polymerization. Our results demonstrated a drastic increase in thrombin, core, and total
platelet area when fibrin polymerization was inhibited with GPRP at arterial shear rates.
The same increase was not observed at venous shear rates, where clot porosity was
elevated and fibrin density was reduced. At arterial shears our results are consistent with
increased thrombin diffusion due to a lack of fibrin leading to an increased area of
activity. However, in the case of clots generated at venous shear rates that have high
porosity we propose that the reduced fibrin facilitated rapid convective removal of
thrombin through the injury site. As a result, the removal of fibrin polymerization
facilitated even greater thrombin removal, causing mild reductions in total and thrombin
area. We hypothesized that thrombin diffusion towards the vessel lumen may also be
limited by binding rather than just physical hindrance.
We investigated this hypothesis by preventing thrombin binding to the high
affinity binding site on the ’-chain of fibrinogen. The ’-chain has been implicated as a
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new clinical biomarker for acute events and chronic diseases such as myocardial
infarctions, coronary artery disease, and deep vein thrombosis [87, 93, 94]. Studies have
shown that thicker fibrin fibers (low thrombin concentrations) have more ’ binding sites
than thinner fibrin fibers (high thrombin concentrations) [95]. These reports, coupled
with our thrombin sensor cleavage results, predict greater ’-thrombin binding at venous
shear rates rather than arterial shear rates due to the differences in the fibrin network.
When we blocked the high affinity binding site on the ’-chain of fibrinogen with a
monoclonal antibody we saw significant increases in total clot, thrombin and core area
only at venous shear rates.

This suggests that at venous shear rates, fibrinogen

preferentially binds thrombin using the ’-chain of fibrinogen to inhibit thrombosis.
Conversely, the low porosity and increased fibrin present in arterial clots prevents
thrombin boundary growth by physically limiting the diffusion of thrombin. While
thrombin binding to A/’ is still present, it alone cannot prevent thrombin mediated clot
growth at arterial shear rates.

These results complement the requirement of fibrin

polymerization at arterial and not venous shear rates.
Interestingly, clots formed at pathological shear rates were also dependent on
fibrin polymerization for regulated growth.

We investigated this dependence by

increasing the wall shear rate from an arterial shear rate (2000 s-1) to a pathological shear
rate (15,000 s-1) that might be found in a stenosed vessel. When the control samples were
compared to the GPRP treated samples, the results demonstrated that fibrin
polymerization was responsible for the reduction in clot growth at pathological shear
rates. This regulation was in align with our results at arterial shears. Increasing the shear
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rate from an arterial to pathological rate increases the dependence on platelet-vWF
interactions [96]. In this case, fibrin limits thrombin mediated platelet recruitment and
may also interfere with platelet-vWF interactions necessary for growth at pathological
shears. This is evident by the increased growth in PPACK samples void of fibrin. This
mechanism may be protective in the event of a ruptured plaque where tissue factor
exposure and shear rates are high [97]. In a similar experiment, the wall shear rate was
increased from a venous shear and whole blood was anticoagulated with PPACK. The
clot grew rapidly, at the leading edge, when shears were increased to pathological rates.
This rapid growth created a zone of low shear which facilitated the local accumulation of
soluble agonists such as ADP and TXA2, as we have previously demonstrated [46]. This
enabled the downstream edge of the clot to contract, a flow sensing response to anchor
the clot to the collagen scaffold.

The contraction in the opposite direction of a

pathological shear rate of 15,000 s-1 was strong enough to prevent embolization in the
absence of fibrin.
While the venous and arterial clots in this study were investigated at the same ΔP,
lower vessel pressures are often found in venous circulation as compared to arterial
circulation [23]. This reduction in vessel pressure may decrease the pressure drop across
the developing clot, which would allow greater thrombin boundary growth and fibrin
formation. The increase in fibrin formation along with the trapping of red blood cells
gives venous clots the label of ‘red clot’. On the other hand, arteries often have a higher
vessel pressure than veins which may increase the transthrombus pressure gradient which
would decrease clot retention of thrombin and the formation of fibrin. This reduction in
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fibrin and the high concentration of platelets gives arterial clots the label of ‘white clot’.
As we have demonstrated these changes in transthrombus pressure gradients would
increase the role of thrombin binding via ’ fibrinogen and decrease fibrin’s role in
hindering thrombin diffusion because of the resulting increase in convective removal.
These observations illustrate the complex balance of both physical and biochemical
parameters that influence the development of clots (Figure 4-11C).
These results have numerous clinical implications, particularly in venous and
arterial thrombosis. Recent reports of interest have shown that IL-6 disproportionately
increases the expression of ’ as compared to A [98].

Elevated IL-6 levels are

associated with increased risk of future MI [99]. The increase in ’-chain fibrinogen
seems to be a mechanism for protection, at least in the venous circulation. Our results in
this study did not indicate any protective effects within clots generated at arterial
conditions but did show protective effects at venous shear rates. This may explain why
lower ’ levels have been implicated as a DVT risk [94]. Future work to determine the
function of the core/shell architecture and role of ’-fibrinogen in different
pathophysiologies will be required to advance and improve patient care.
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Figure 4-11

Human thrombi develop a core and shell architecture that mimic the
architecture of clots developed in vivo.

Human clots developed in vitro (A) and mouse clots developed in vivo (B) were outlined
by imaging the clots using platelet (blue) and P-selectin antibodies (red). A heat map was
used in both images to illustrate the localization of thrombin sensor cleavage (light blue =
low intensity and white = high intensity). A schematic representing the regulation of
thrombin and small molecules ADP and TXA2 demonstrates both the physical and
biochemical transport regulations observed within clots (C). (ε, porosity; k, permeability,
D, diffusivity, p*, activated platelet)
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Chapter 5 : Rapid on-chip recalcification and drug dosing of citrated whole blood
using microfluidic sheath flow
5.1 Introduction
Exposure of extracellular matrix (ECM) proteins at a site of vascular injury elicits
a hemostatic response from both platelets and coagulation proteins. Primary hemostasis
or platelet plug formation is simultaneously accompanied by the generation of thrombin
and fibrin via the coagulation cascade [1]. One factor in this response is the local wall
shear stress (τw). Blood experiences both high (arterial) and low (venous) shear stress as
it flows throughout the vasculature [23]. In cylindrical vessels, wall shear stress is
uniform around the circumference of the vessel. Recreating this constant shear stress at
an injury site in a rectangular microfluidic channel is difficult due to the corners.
Sheathing the blood flow from the corners may result in an injury with a more
physiologic architecture while offering an opportunity to diffuse small molecules into the
blood via the sheathing buffer.
Platelet and coagulation assays most commonly require whole blood to be drawn
directly into sodium citrate, an anticoagulant that chelates Ca2+ [101, 102]. Prior to most
clinical assays such as PT and aPTT, citrated blood is recalcified to restore platelet and
coagulation function [103, 104].

Unfortunately, many microfluidic or flow assays

neglect recalcification prior to flow [105]. While previous microfluidic assays have
demonstrated platelet and coagulation function under various shear rates and pressure
gradients [46, 86], there have been a limited number of microfluidic studies focusing on
the recalcification of citrated whole blood and the resulting platelet and coagulation
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function under flow conditions. These experiments are important because of the clinical
use of citrated whole blood and the recent advances in assays utilizing flow such as the
PFA-100. This assay measures the time required for citrated whole blood to close a
narrow opening in a collagen membrane. Without recalcification, the citrated blood used
in the PFA-100 limits the system measurement to only platelet dysfunction [106].
Currently, there are no devices capable of reproducing the recalcification of citrated
whole blood and evaluating the effects on platelet and coagulation function under flow
conditions. A device capable of these characteristics would be important for clinically
relevant flow assays utilizing citrated whole blood.
We describe the design and characterization of a converging trifurcation
microfluidic device capable of recalcifying or drug-dosing whole blood under flow
conditions. The device permits measurements of platelet and coagulation function at
varying levels of recalcification or platelet inhibition along the length of the channel.
Localized collagen or collagen/tissue factor (TF) surfaces initiated platelet and
coagulation responses at a constant wall shear stress. This was produced by sheathing
anticoagulated whole blood with buffer (±Ca2+). During recalcification of citrated whole
blood, both platelet and coagulation response demonstrated a dependence on the
reconstitution of calcium. Citrated whole blood incubated for longer times prior to
recalcification resulted in a priming of the intrinsic pathway (due to Factor XIIa
generation in the absence of calcium). Both platelet and coagulation responses were
initiated faster and magnified at the final time point. The addition of MRS-2179, a
platelet P2Y1 antagonist, to the buffer sheath flow resulted in a dose dependent inhibition
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of platelet deposition in a single channel. The calculated IC50 for this dose response
correlated well with previous reports. The device we report demonstrates the ability to
recalcify citrated whole blood under flow as well as the ability to provide accurate single
channel measurements of platelet antagonist IC50 values. This is the first device we have
knowledge of that can provide both of these characteristics.
5.2 Materials and Methods
5.2.1 Fabrication
Silicon wafers (D = 100 mm, WRS Materials) were spin coated with a 60 µm
layer of negative photoresist (KMPR 1050, MicroChem Corp.). Following a 20 min soft
bake and UV exposure, the substrate was baked for an additional 4 min at 100 °C. The
wafer was then developed using AZ® 300 MIF (AZ Electronic Materials USA Corp.).
Devices were fabricated using polydimethylsiloxane (PDMS) (Ellsworth Adhesives) at a
10 : 1 ratio of base to curing agent. All inlet and outlet ports were cored using 0.75 mm
I.D. corers (Harris Uni-Core™, Ted Pella, Inc.).

Connections between the PDMS

devices and 250 μL syringes (Hamilton Company) were made using 90°, 23 gauge x 1/2”
length blunt needles (Small Parts) and 0.020” ID x 0.060” OD tubing (Cole-Parmer).
Devices were reversibly sealed to the glass slides using a vacuum pump and the
previously mentioned tubing.
5.2.2 Design
The trifurcation device utilized in these studies was designed to sheath whole
blood with buffer flows. The device consisted of three inlets and one outlet. The center
inlet is described as the blood inlet and the two side inlets are described as the buffer
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inlets. The blood entrance length and buffer entrance lengths were 3 mm and 1.8 mm
respectively. Channel widths were 250 μm for the blood inlet and 110 μm for the buffer
inlets. At the trifurcation point, the buffer inlets were introduced at a 20° angle to the
blood inlet. Following the trifurcation of the three inlets (RBlood= 1000 μm, RBuffer=750
μm), the channel widened to 300 μm. The channel was 44.8 mm in length and exited at a
single outlet (RExit=1000 μm). Each chip was designed with two channels parallel to each
other separated by 8 mm.

Surrounding the channels were designed post regions

(RPost=500 μm) to support vacuum sealing of the chips to glass slides (75 mm x 38 mm,
Fisher Scientific).
In addition to the trifurcation device, protein patterning devices were also
designed. These devices used the same dimensions as the trifurcation template to provide
patterned strips at consistent distances from the trifurcation point.

Two patterning

devices were utilized, one with 7 channels and another with 8 channels. Both the 7
channel and 8 channel devices were designed with 250 µm channels perpendicular to the
direction of the trifurcation flow with one inlet (R=1000 μm) and one outlet (R=1000
μm). The channels were 11 mm in length and separated by 6 mm (7 channel design) or
5.5 mm (8 channel design). This feature allowed one device to pattern protein at one or
more locations on two independent trifurcation channels. Similar to the trifurcation
device, the patterning devices were designed with post regions to support vacuum
assisted sealing to the glass slide.
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5.2.3 Blood Collection
Phlebotomy was performed in accordance with the University of Pennsylvania’s
IRB. Human blood was collected from healthy volunteers, self reporting as alcohol and
medication

free.

Blood

was

anticoagulated

with

100

µM

Phe-Pro-Arg-

chloromethylketone (PPACK) (Haematologic Technologies Inc.) or concentrated citrate
solution (1 part anticoagulant to 9 parts whole blood) (Sigma-Aldrich). Citrated whole
blood was occasionally supplemented with 40 μg ml-1 corn trypsin inhibitor (CTI)
(Haematologic Technologies Inc.). Studies devoid of TF utilized PPACK whole blood
and 1 µg ml-1 of a fluorescently conjugated anti-CD41 monoclonal antibody (Abd
Serotec). Studies including thrombin utilized citrated whole blood ± CTI. These samples
were prepared with the previously mentioned anti-CD41 monoclonal antibody as well as
0.0125 mg ml-1 of a fluorescently conjugated fibrinogen (Invitrogen).
5.2.4 Operation
Glass slides were treated with Sigmacote® (Sigma-Aldrich) to impede blood
clotting and the adsorption of basic proteins. Following surface treatment, a patterning
device was vacuum sealed to the slide. Collagen (Chrono-log Corp.) was patterned on
the slides by pulling the solution through the desired channel(s). Immediately afterwards,
0.5% bovine serum albumin (BSA) was rinsed through the channel(s) to remove free
collagen.

In experiments requiring tissue factor (TF), the patterned collagen was

incubated with TF solution (Dade Innovin Reagent, Siemens) following the BSA rinse.
After incubating for 30 min, the channel was rinsed with 0.5% BSA and the patterning
device was removed.
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The trifurcation device was placed directly on top of the patterned collagen. The
horizontal edge was aligned with the glass slide and the vertical edge was aligned to fit
both flow channels perpendicular to the patterned collagen. Syringes were loaded with
anticoagulated whole blood and HEPES buffer (HBS) supplemented with methyl
cellulose (0.02%, Sigma-Aldrich). The addition of methyl cellulose increased the buffer
viscosity to the same viscosity as whole blood (3 cP) [47]. In experiments investigating
dye diffusion, fluorescein isothiocyanate (FITC) (Sigma-Aldrich) was loaded in the
sheath buffer and Texas Red® conjugated albumin (BSA) (Invitrogen) was loaded in the
blood or buffer in the center inlet. Recalcification experiments used buffer loaded with
30 mM Ca2+ while drug dosing experiments used buffer with physiologic calcium
concentrations (2.4 mM Ca2+) and 10 µM MRS-2179 (Tocris Bioscience), a potent P2Y1
inhibitor [107].
A constant volume syringe pump (PHD Ultra, Harvard Apparatus) was used to
perfuse the anticoagulated whole blood syringe as well as both buffer syringes. The
equal flow rates set the width of each fluid to 100 µm with the center inlet containing the
whole blood and the two side inlets containing buffer. Wall shear rate was controlled by
adjusting the flow rate appropriately. All experiments in this study were performed at
room temperature and set at a constant wall shear rate (600 s-1). Glass slides with
vacuum sealed devices were positioned on an inverted microscope (IX81) (Olympus
America Inc.) and imaged with an ORCA-ER CCD camera (Hamamatsu).
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5.2.5 Finite Element Analysis
COMSOL Multiphysics was used to simulate fluid flow and solute transport
within the trifurcation device. Laminar fluid flow was modeled using the stationary
Navier-Stokes equation while the solute transport was modeled using the conservation
equation for chemical species. Both blood and buffer were defined with equal viscosity
(µ=3 cP) and density (ρ=1060 kg m-3). Diffusion coefficients were defined for FITC
(DFITC= 6.4 x 10-10 m2 s-1 in water) [108], BSA (DBSA= 6.1 x 10-11 m2 s-1 in sodium
phosphate/chloride buffer) [109], and calcium (DCa2+= 7.9 x 10-10 m2 s-1 in water) [110]
after they were adjusted using the Stokes-Einstein Relation to account for the increased
viscosity of blood/buffer (µ=3 cP). Additionally, the diffusion coefficient for MRS-2179
(DMRS-2179= 1.5 x 10-10 m2 s-1, µ=3 cP) (Stokes-Einstein Relation) was defined and the
flow rates for blood/buffer were set (Q=1.91 μL min-1). The model was validated by
simulating the normalized area under the curve in the middle 100 μm of the channel for
both FITC and BSA diffusion. Simulated values were collected along the length of the
channel and compared to experimental measurements. The validated model was used to
predict calcium and MRS-2179 diffusion along the length of the channel for a wall shear
rate of 600 s-1. All simulations were performed with a 2D model using a shallow channel
approximation with a thickness equal to the height of the microfluidic channel (h=60
µm). The approximation allowed the model to simulate the conditions at the center of the
channel in the z-direction (h=30 µm), where all experimental measurements of the
fluorescent species were imaged.
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5.3 Results
5.3.1 Diffusion controlled recalcification of citrated whole blood
We designed a trifurcated microfluidic device to analyze platelet and coagulation
function at a controlled wall shear stress (Figure 5-1A). The center channel and two side
channels were simultaneously perfused with citrated whole blood and 30 mM Ca2+ buffer
(μ = 3 cP) respectively (Figure 5-1B). The calcium buffer sheathed the blood flow
which prevented the blood from contacting the patterned collagen/TF surface near the
corners of the channel, where τw = 0 dynes/cm2.

Instead, the wall shear stress

experienced by the blood remained constant (Figure 5-2), while the buffer shear stress
diminished as it approached the corners. This flow design enabled the constant wall
shear stress found in cylindrical capillaries or veins to be recreated in a rectangular
microfluidic device.
At the trifurcation entrance, the buffer and blood streams merged as illustrated
with FITC dye (Figure 5-1C) and a COMSOL simulation predicting Ca2+ diffusion
(Figure 5-1D). The 20° entrance angle and laminar fluid flow (Re=0.14) produced sharp
interfaces between the blood and buffer. The low Reynolds number flows associated
with microfluidic devices minimized convective mixing [111].

Therefore, diffusion

controlled the concentration gradients found across the blood and buffer flows. FITC dye
was added to the buffer flow stream and the concentration in the middle 100 μm of the
channel was measured in whole blood or buffer. The normalized area was determined
along the length of the channel (Figure 5-1E). At 42 mm downstream of the trifurcation
entrance, 62.5% of the maximum dye area was obtained in whole blood. The COMSOL
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simulation recreating this experiment predicted this measurement within 0.5%. In a
similar experiment, Texas Red® conjugated BSA was added to whole blood or buffer in
the center flow stream. Measurements of the normalized BSA area in the middle 100 μm
of the channel were made along the length of the channel (Figure 5-1F). Only 17.7% of
the maximum normalized BSA area was removed from the whole blood at the final
measurement point (Y=42 mm). Again, this measurement was predicted within 0.5%
using a COMSOL simulation.

These experiments validated the COMSOL model used

to simulate the mixing of soluble species in each of the fluid streams. Line scans of FITC
dye and BSA at each position illustrated the mixing of these two tracers (Figure 5-3).
The order of magnitude difference in their diffusion coefficients explains the disparity
[108, 109].
After the model was validated, it was used to simulate the minimum concentration
of Ca2+ in the citrated whole blood along the length of the channel (Figure 5-1G). The
wall shear rate controlled the minimum Ca2+ concentration by decreasing the time the
fluid remained in the channel (tf). A 30 mM Ca2+ buffer solution provided a maximum
centerline concentration of 20 mM Ca2+. At a wall shear rate of 600 s-1, a minimum Ca2+
concentration of 9 mM was reached prior to the first patterned collagen/TF surface. This
Ca2+ concentration was sufficient to recover a free calcium concentration equivalent to
CTI blood [112].
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Figure 5-1

A trifurcated microfluidic device to recalcify citrated whole blood
under flow.

A trifurcation microfluidic device was designed to recalcify citrated whole blood prior to
contact with patterned collagen ± TF surfaces (A). Citrated whole blood was sheathed
with 30 mM calcium buffer (µ=3 cP) at the entrance of the trifurcation design (B). The
sharp gradients between the buffer and blood were illustrated, at the entrance, using FITC
dye (C). The calcium gradients at the trifurcation entrance were simulated using
COMSOL (D). The normalized FITC dye (E) and BSA (F) area were measured and
simulated in the middle 100 µm of the channel at discrete points along the channel
(depicted in A). Minimum calcium concentrations in the middle 100 µm of the channel
were simulated in COMSOL for wall shear rates ranging from 200 s-1 to 2000 s-1 (G).
Fluid transit times (tf) along the length of the channel were calculated for each shear rate.
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Figure 5-2

Whole blood sheathed in buffer experienced a constant wall shear
rate.

COMSOL was used to calculate wall shear rate across the 300 µm trifurcation channel.
In the blood region or the middle 100 µm of the channel, the wall shear rate remained
constant. Alternatively, the buffer regions experienced shear rate gradients due to corner
effects. Constant wall shear rates experienced by the blood region mimic in vivo injuries
where cylindrical vessels remove corner effects.
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Figure 5-3

FITC and BSA line scans within the trifurcation channel.

Line scans of FITC fluorescence intensity (A) and Texas Red BSA fluorescence intensity
(B) were averaged across the trifurcation channel. Measurements were made at eight
locations beginning at the trifurcation point (0 mm). At a wall shear rate of 600 s-1, FITC
dye diffusion progressed rapidly along the length of the channel. Conversely, channel
transit times limited protein diffusion (BSA).
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5.3.2 Recalcification of citrated whole blood under flow recovers platelet and
coagulation function
Citrated whole blood was sheathed with 30 mM Ca2+ buffer at a wall shear rate of
600 s-1.

Collagen/TF was patterned at a distance of 6 mm downstream from the

trifurcation entrance. Platelet (red) and fibrin(ogen) (green) accumulation were measured
dynamically at the 250 μm patterned surface (Figure 5-4). After 4.2 min of flow, platelet
aggregation was evident while fibrin(ogen) was not (Figure 5-4A).

Following an

additional 3 min of flow, fibrin(ogen) accumulated at the downstream portions of the
clot in areas free of platelets (Figure 5-4B). Platelet and coagulation activity continued
to increase after 10 min of flow (Figure 5-4C). The constant shear gradient generated in
the trifurcation device removed the corner effects observed during full channel flow
(Figure 5-5).
In order to demonstrate proper recalcification, platelet and coagulation function
were measured by perfusing whole blood anticoagulated with CTI and citrate with and
without calcium in the sheath buffer (Figure 5-6). Collagen/TF surfaces were patterned
at 7 positions along the length of the channel. Platelet and fibrin(ogen) fluorescence
intensities were measured at each localized injury site (L=250 m, W=100 μm). Both
platelet and fibrin(ogen) accumulation required Ca2+ in the sheath buffer.

Platelet

aggregation with recalcification buffer began after 6 minutes of flow (Figure 5-6A).
Similar platelet fluorescence intensities were not reached until 15 minutes without
recalcification buffer (Figure 5-6B). On average, final platelet fluorescence intensities
were reduced by 87.3 ± 9.3% when Ca2+ was absent. Fibrin(ogen) accumulated shortly
after platelet aggregation in the recalcification experiment (Figure 5-6C).
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In the

experiment without Ca2+, fibrin(ogen) accumulation was completely abolished yielding a
reduction of 99.0 ± 0.9% (Figure 5-6D). When the [Ca2+] was calculated to be >16 mM
in the blood, the fibrin(ogen) fluorescence intensity remained stable. Interestingly, this
was the same concentration where the difference between the time to 25% of the
maximum fluorescence intensity (fibrin(ogen) t25% - platelet t25%) reached a global
minimum (Δt25%=0.2 min). These studies demonstrated the dependence of recalcification
buffer for proper platelet and coagulation function on patterned collagen/TF surfaces.
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Figure 5-4

Whole blood recalcified under flow recovers platelet and coagulation
function.

A strip of collagen/TF was patterned downstream (Y=6 mm) of the trifurcation entrance.
Citrated whole blood was recalcified under flow (600 s-1) with 30 mM Ca2+ buffer.
Platelet (red) and fibrin(ogen) (green) accumulated at the localized injury site, illustrated
at the 4.2 min (A), 7.3 min (B), and 10.4 min (C) time points.
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Figure 5-5

Buffer sheath flows eliminate corner effects on clot formation.

Line scans of normalized platelet and fibrin(ogen) fluorescence intensity were averaged
at a patterned collagen strip (250 µm) for full channel flow (A) and buffer sheathed flow
(B). The full channel flow illustrated the effects of wall shear rate dropping to zero.
Both platelets and fibrin(ogen) accumulate in the corners (0 µm and 250 µm). The
buffer sheathed flow yielded maximum platelet and fibrin(ogen) accumulation near the
center of the flow.
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Figure 5-6

Recalcification is required for proper platelet and coagulation
function.

Whole blood anti-coagulated with both CTI and citrate was sheathed in buffer (µ=3 cP) ±
30 mM Ca2+. Blood and buffer ± Ca2+ were perfused (600 s-1) across seven, equally
spaced, 250 µm collagen/TF strips each identified by the distance in millimeters from the
entrance of the channel. Dynamic measurements were collected for both platelet (A-B)
and fibrin(ogen) deposition (C-D) at each location.
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5.3.3 Intrinsic generation of factor XIIa primed platelet and coagulation activity in
citrated whole blood
The addition of CTI to whole blood provided selective inhibition of factor XIIa
[113]. This impedes the initiation of the intrinsic pathway. Citrated whole blood alone
does not prevent the generation of factor XIIa because factor XII is activated
independently of calcium [114]. The effect of factor XIIa on platelet and coagulation
activity were investigated by measuring platelet and fibrin(ogen) accumulation on a
collagen/TF surface (Y= 6 mm) with citrated blood incubated for 5 min or 30 min after
phlebotomy. Platelet aggregation initiated 5 min faster when citrated whole blood was
incubated for 30 min rather than 5 min (Figure 5-7A). Final platelet aggregation,
measured by final fluorescence intensity, was increased by 159%. Likewise, after a 30
min incubation fibrin(ogen) accumulation initiated 2 min faster with an 86.6% increase in
final fluorescence intensity (Figure 5-7B). Measurements made with citrated whole
blood incubated for 5 min were similar to measurements made with whole blood
anticoagulated with CTI and citrate. The extra incubation time (25 min) facilitated the
generation of factor XIIa. This primed the intrinsic pathway resulting in accelerated
platelet and fibrin(ogen) accumulation at the injury site upon recalcification.
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Figure 5-7

Incubation of citrated whole blood primed platelet and coagulation
activity via factor XIIa.

Citrated whole blood was incubated for either tincubation=5 min or tincubation=30 min
following phlebotomy. A 30 mM Ca2+ buffer sheathed and recalcified the citrated whole
blood prior to the collagen/TF strip (Y= 6 mm). Platelet (A) and fibrin(ogen) (B)
deposition was measured and compared for both incubation times.

132

5.3.4 Single channel IC50 measurement of MRS-2179 under flow
Whole blood anticoagulated with PPACK (a potent thrombin inhibitor) was
perfused through the trifurcation device. Buffer with a physiologic calcium concentration
(2.4 mM) was used to sheath the blood along the length of the channel.

The %

hematocrit of the whole blood was calculated at each patterned collagen surface (Figure
5-8A). As the blood travelled down the channel the red blood cells dispersed and the %
hematocrit dropped slowly. At the final collagen strip the % hematocrit was reduced by
~13% (assuming an initial % hematocrit of 45%). After the % hematocrit dropped below
38%, the platelet deposition decreased significantly (Figure 5-8B). While boundary
depletion may not be excluded, this effect was not observed in studies with CTI and/or
citrate. The presence of thrombin in those studies may have masked any observable
platelet depletion.
In a related experiment, we investigated the effect of MRS-2179 (a platelet P2Y1
antagonist) on platelet deposition. The 2.4 mM Ca2+ buffer was supplemented with 10
μM MRS-2179 and platelet fluorescence intensity was measured at 8 collagen strips
downstream of the trifurcation entrance. The MRS-2179 drastically reduced platelet
fluorescence intensity at all 8 positions as compared to buffer without MRS-2179 (Figure
5-8B). The % platelet inhibition was calculated at each position and compared to the
simulated [MRS-2179] along the length of the channel (Figure 5-8C). The calculated
IC50 (0.155 μM) compares favorably to previous IC50 measurements made under flow
conditions (0.173 μM) [70]. The length of the channel used in this design made it
possible to study MRS-2179 concentrations varying over an order of magnitude. This
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facilitated accurate measurements of an IC50 value below 1 µM. The trifurcation device
used in this study is the first device capable of measuring platelet antagonist IC50 values
with a single channel. It is also the first device to accomplish these measurements using
automated mixing to achieve a range of concentrations.
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Figure 5-8

Single channel IC50 measurement.

The % hematocrit of whole blood sheathed with buffer was measured in the middle 100
µm of the channel along the entire length (A). A 2.4 mM Ca2+ buffer ± 10 µM MRS2179 (platelet receptor P2Y1 antagonist) was used to sheath PPACK whole blood prior to
collagen exposure. Platelet deposition was measured at eight evenly spaced collagen
strips for buffer with and without MRS-2179 (B). % Platelet inhibition and predicted
MRS-2179 concentration were determined along the length of the channel (C).

135

5.4 Discussion
The laminar flows (Re ~1) found in microfluidic devices make convective mixing
extremely difficult.

Often times this characteristic mixing time is a limitation of

microfluidic devices that can only be altered by the addition of active or passive mixers
[115]. Rather than working against this limitation, we used long channel lengths to take
advantage of diffusional mixing. We designed a trifurcation microfluidic device that
utilizes differences in species diffusion coefficients to reach varying levels of
concentrations along the length of a channel. Previous work with trifurcation designs
have focused on concentrating or separating cells by utilizing acoustics and dextran/red
blood cell affinities respectively [116, 117]. Instead, our work exploited the differences
in protein and small molecule diffusion rates to recalcify or antagonize human whole
blood under flow. This is the first reported device to recalcify citrated whole blood and
measure platelet IC50 values under flow conditions without premixed concentrations of
Ca2+ or antagonist in whole blood. Recalcification of citrated whole blood and mixing of
platelet antagonist under flow minimizes user error in measurements that may have
clinical implications.
Platelet and coagulation assays currently adopted by clinicians use blood products
primarily anticoagulated with sodium citrate [101, 102]. The main advantage of using
citrated blood is the increased storage time and control of the initiation time
(recalcification). Standard assays such as the aPTT and PT both use citrated blood but
neither incorporate flow. These tests are forced to extrapolate their data in an attempt to
understand how clotting occurs under flow.
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The device described here not only

incorporates flow but it also provides a measurement for both platelet and coagulation
function. In addition, recalcification under flow maintains a constant initiation time that
eliminates the generation of activated coagulation factors prior to exposure of the
collagen/TF surface. This feature provides repeatable recalcification of citrated blood
without the need of an expert technician. Along with proper recalcification, the designed
device allows for single channel IC50 measurements. Platelet or coagulation antagonist
IC50 values can be measured at submicromolar accuracy as demonstrated by our MRS2179 measurement.

This approach may be useful for future designs that desire

personalized drug dosing.
The implications of this device are not limited to citrated blood recalcification and
platelet IC50 measurements. This device also recreates constant wall shear stress injuries
as experienced by injured cylindrical vessels in vivo. Corner effects in rectangular
microfluidic devices cause gradients in wall shear stress that facilitate platelet adhesion to
collagen during whole blood perfusion [31]. Removing this shear gradient eliminates
lower shear zones where platelets and coagulation factors accumulate.

Instead, as

platelets accumulate at a constant wall shear stress they are forced to generate their own
zones of lower shear stress to facilitate coagulation factor accumulation and fibrin
generation. This represents a scenario experienced by an injury in vivo. In the future,
studying the intrinsic and extrinsic generation of fibrin at constant wall shear stress might
help distinguish their dependence on platelets at higher and lower shear stresses.
While solute diffusion was the primary means of investigation for this study, the
length and mixing properties of this device make it a valuable tool for control of
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temperature, pH, and hematocrit levels in future work.

Investigating the effects of

temperature (hypothermia), pH (acidosis), and hematocrit on platelet and coagulation
function make this device suitable for studying the varying levels of trauma [118].
Current assays such as thromboelastometry overestimate the integrity of coagulation
under varying combinations of these symptoms which make new assays desirable [119].
This device also has the ability to determine the influence of erythrocyte aggregation, a
typical consequence of trauma [120], on clot formation. While red blood cell aggregation
[121], and deformability has been studied in sepsis models [122], this system would
permit further investigation on their roles in thrombosis and hemostasis. There have been
very few microfluidic devices developed for addressing the severity of these symptoms
and the effects on platelet and coagulation function. Using this device to investigate
these symptoms in varying combinations could reveal new insights for the treatment and
diagnosis of patients experiencing trauma.
5.4 Conclusions
We have demonstrated the design and novel implications of a device to rapidly
recalcify citrated whole blood and dose anti-platelet drugs using buffer sheath flows.
Whole blood anticoagulated with sodium citrate was recalcified under flow with buffer
sheath flows containing Ca2+.

COMSOL simulations and measurements of

platelet/fibrin(ogen) deposition with and without Ca2+ in the sheath buffer confirmed that
recalcification was completed prior to being exposed to patterned collagen/TF surfaces
downstream. The addition of CTI to citrated whole blood prevented the priming of the
intrinsic coagulation protein XIIa when blood was incubated for 30 min after
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phlebotomy. The long channel lengths used in this design enabled IC50 measurements
for the platelet antagonist MRS-2179.

Measurements made agreed with previously

reported values which illustrates the devices submicromolar accuracy. The designed
device provides a unique platform for studying constant wall shear stress injuries
following whole blood recalcification or platelet inhibition under flow.
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Chapter 6 : Future Work
6.1 Effect of platelet contraction on clot growth
The device designed in Chapter 2 has the ability to study the architecture of clots
developed under physiologic conditions, as illustrated in Chapter 4. Our work in Chapter
4 defined both physical and biological conditions in which thrombin mediated clot
growth was regulated. Another important aspect of clot development, which was only
briefly addressed in Chapter 4, is the ability of the clot to contract. Clot contraction has
an important role in preventing blood loss and anchoring the clot to the injury site to
prevent embolism [59, 123]. In vivo results have implicated that clot consolidation via
contraction aids in retaining solutes by decreasing their transport within the architecture
of the clot [75]. Interestingly, human platelets are larger than mouse platelets [124]. This
property may change the role of platelet contraction in human blood clots.
In order to investigate the role of clot contraction on the resulting clot
architecture, we performed a preliminary set of experiments in the absence and presence
of 10 µM blebbistatin, a potent myosin IIa inhibitor (Figure 6-1) [68]. Whole blood
anticoagulated with CTI was perfused across a collagen/TF scaffold as previously
described in Chapters 2-4. The wall shear rate was set at 400 s-1 and the transthrombus
pressure gradient was maintained at 20 mm Hg. Total clot, fibrin, and P-selectin positive
area were dynamically calculated throughout the experiment. The total clot area of clots
treated with blebbistatin grew to a greater extent (1.48-fold, P<0.01) than control clots
(Figure 6-1A).

Their initial clot area remained unchanged until 6 min of growth

(P<0.05). The fibrin area did not significantly change in the presence of blebbistatin
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(Figure 6-1B).

% P-selectin positive area was significantly delayed (t=1.5 min,

P<0.025) and reduced (15.1%, P<0.05) when clot contraction was inhibited (Figure
6-1C).
These results indicate that clot contraction is important for clot consolidation as
evident by the increase in total clot area in the presence of blebbistatin. The impact on
thrombin generation and localization is less clear.

The fibrin polymerization data

supports a claim that thrombin removal may not have been increased because the total
fibrin area remained constant. In contrast, the delay in % P-selectin area and decrease in
final % P-selectin positive area may have been a result of decreased thrombin retention.
In order to determine the role of clot contraction, several additional experiments will need
to be performed. As with our work in Chapter 4, the clot architecture will need to be
examined at both venous and arterial shear rates to determine the role of clot contraction.
The different platelet packing and fibrin densities could drastically influence platelet
contraction. In addition, the thrombin sensor will need to be used to determine the
localization of thrombin within the resulting clots. This will describe the presence of
thrombin in greater detail then the fibrin polymerization results. It may also be beneficial
to increase the concentration of blebbistatin to 100 µM.

Previous literature has

demonstrated different effects of blebbistatin at 10 µM and 100 µM [68].

These

experiments are required to decipher the role that clot contraction has on thrombin
mediated clot growth in human blood clots.
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Figure 6-1

Clot contraction reduces total clot height and increases the % Pselectin positive area of the clot.

Clot growth was investigated during 10.5 min of CTI whole blood perfusion (400 s-1)
over a collagen/TF scaffold. Whole blood was treated with buffer or 10 µM blebbistatin
prior to perfusion. Total platelet area (A) and fibrin area (B) were calculated using a
fluorescently conjugated, platelet or fibrin specific antibodies respectively. % P-selectin
positive area, as defined by a P-selectin antibody, was calculated based on the P-selectin
positive area and total clot area for both conditions (C).
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6.2 Model for evaluating the effect of inflammation on clotting
Throughout Chapters 2-4 we have described a microfluidic device capable of
studying clot growth and architecture at controlled wall shear rates and transthrombus
pressure gradients. While this device excels in models of hemostasis and thrombosis, it
may also be appropriate for studying the inflammatory response, an additional phase of
wound healing. To date, there are very few in vitro models capable of studying the
interaction of flow developed blood clots and neutrophils. Neutrophils are migratory
leukocytes that respond to bacterial infection at the site of injuries in a process known as
chemotaxis [125]. Their migration towards the infected area is controlled by chemokines
such as TNF-α and IL-8 [126, 127]. Lipopolysaccharides (LPS), an endotoxin located on
gram-negative bacteria also has a prominent role in initiating the immune response. LPS
is known to cause a response in both platelets and neutrophils. The toll-like receptors
(TLR-4) on platelets facilitate a response to LPS resulting in increased platelet binding to
fibrinogen and neutrophil extracellular trap (NET) activation [128, 129]. NET’s are
composed of chromatin fibers and have been implicated in increased DVT risk due to
elevated thrombin generation [130]. In addition, LPS can also cause other white blood
cells to release chemokines to attract neutrophils to the site of bacterial infection [131].
Understanding the migratory and NET releasing response of neutrophils, at the site of
injury, may be a valuable tool for advancing patient care, specifically in DVT and sepsis.
Our preliminary investigations into neutrophil migration (Figure 6-2) and LPS
induced activation of platelets and neutrophils (Figure 6-3) were performed in the device
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we designed and outlined in Chapter 2. Interestingly, our first observation of neutrophil
migration came when we observed a white blood cell migrating across a developed clot
while studying clot permeability. In this study we perfused CTI whole blood (1000 s-1)
over a collagen/TF surface with a transthrombus pressure gradient of 20 mm Hg. After
~14 min of flow we turned a valve to change the whole blood to buffer to visualize the
fluorescent pulse travel through the permeable structure. Throughout the experiment, we
followed the migration of an adhered leukocyte (Figure 6-2A).

The distance the

leukocyte travelled remained relatively unchanged throughout the buffer pulse (Figure
6-2B). In contrast, there was an obvious change in distance from the starting point when
the buffer pulse was perfused through the clot (Figure 6-2C). Prior to the buffer, the
leukocyte travelled in a distinct manor towards the collagen/TF scaffold. As the whole
blood transitioned to buffer (t=14 min), the direction of movement dissipated with the
leukocyte moving in a stochastic manner. As the blood flow was reestablished (t=20
min), the leukocyte began to migrate towards and into the collagen scaffold (Figure
6-2A). These results lead to a hypothesis that leukocyte chemotaxis requires plasma, in
the absence of endothelial cells. To further investigate this process, several experiments
would need to be performed. First, the system may need to be modified to recruit
additional leukocytes to the injury site. This could be accomplished by reducing the
shear rate to a venous shear rate or by adding chemoattractants such as TNF-α and IL-8
to the collagen/TF scaffold. Second, the modified system could be used to observe the
migration of multiple leukocytes while whole blood was transitioned to buffer or whole
blood. Finally, inhibiting proteases (cathepsin G or α-chymotrypsin) or receptors (fMLP
or Fc) responsible for leukocyte chemotaxis could help to define which proteases or
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receptors are required for this process [132, 133]. These experiments could be used to
determine which components of plasma are responsible for directing leukocyte migration.
The other inflammatory response that we investigated was the LPS induced
activation of platelets and neutrophils at the site of an injury (Figure 6-3). In this
preliminary experiment, we perfused CTI whole blood (100 s-1) across a collagen/TF
(Figure 6-3A) or a collagen/TF/LPS scaffold (Figure 6-3B).

Average clot height

(Figure 6-3C) and clot associated neutrophil counts (Figure 6-3D) were calculated
throughout the duration of the experiment. Platelets were imaged with fluorescently
conjugated CD41 antibodies and neutrophils were imaged with fluorescently labelled
CD18 antibodies. Interestingly, the clot formed on the collagen/TF/LPS scaffold grew
2.3-fold larger than the clot formed on the collagen/TF scaffold. The growth of the clots
did not begin to differentiate until after 4 min of flow. At this time, clot growth remained
constant on the scaffold with LPS while clot growth on the scaffold free of LPS began to
dissipate. The delay in growth rate changes may be due to the increase in clot associated
neutrophils (27-fold more) in the clot formed on the LPS scaffold. Future experiments
will need to be performed to evaluate the effect of LPS on both platelets and neutrophils.
In order to determine the effect of LPS independently on platelets, we will inhibit
neutrophil activation with proepithelin (PEPI) and secretory leukocyte protease inhibitor
(SLPI) [134]. This will allow us to study clot formation dependent solely on LPS without
the influence of activated neutrophils. In addition to these studies, we will also add
antibodies for P-selectin expression and thrombin activity. These markers will provide
insight into the regulation of thrombin in clots formed in the presence of LPS. Finally,
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NET formation and influence on clot structure will be studied with Sytox green staining.
These measurements will provide information regarding the influence of NET formation
on platelet recruitment and thrombin generation. Further investigations of neutrophil
migration and interactions with developing clots will be important for understanding the
mechanisms of clot formation in patients at risk for DVT and sepsis. Moving forward,
we will be able to use the device that we developed and characterized in Chapters 2-4 to
study the inflammation stage of wound healing under physiologic conditions.
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Figure 6-2

Plasma perfusion through blood clots is required for white blood cell
chemotaxis towards the injury site.

CTI whole blood was perfused across a collagen/TF scaffold at 1000 s-1 for ~14 min.
Following clot development, buffer was pulsed through the system (14 min-20 min)
before whole blood was reestablished. A white blood cell (green) was tracked throughout
the growth of the clot and the pulse of buffer (A). The total distance the white blood cell
travelled (B) and the distance the white blood cell moved from the starting point (C) were
tracked throughout the experiment.

147

Figure 6-3

LPS embedded in a collagen/TF scaffold induces larger clot growth at
venous shear rates.

Whole blood anticoagulated with CTI was perfused at the venous shear rate of 100 s-1
over a collagen/TF scaffold in the absence (A) or presence (B) of 100 pg/mL LPS.
Average clot height was calculated in both conditions using a platelet specific
monoclonal antibody (C). Average clot associated neutrophil count was estimated by
using a fluorescently conjugated CD18 antibody to calculate total neutrophil area. This
area was divided by the average area of a neutrophil based on diameter.
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